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This thesis describes the treatment on compassionate grounds of 15 
children with diffuse intrinsic pontine glioma (DIPG), which is a lethal 
cancer of middle childhood. Children were treated using chemotherapy 
infused directly into the pons by chronic, intermittent convection enhanced 
delivery (CED). The use of an implantable drug delivery system connected 
to a transcutaneous drug administration port enabled repeated infusions 
without repeated surgery. Previous experience of pontine infusion in 
children with DIPG demonstrates that treatment is associated with 
neurological side-effects. As a new treatment for neurological disease, the 
cause of these side-effects is unknown. The possible causes can be 
broadly categorised into those due to the pharmacological action of the 
drug and the physiological impact of the infusion. This thesis describes how 
a novel neurological assessment scale was developed, implemented and 
evaluated to understand the toxicity of pontine infusion. Analysis of the 
results suggests that the majority of side-effects in brainstem CED are 
caused by the infusion. Predictive factors of neurological recovery relate to 
how the infusion is performed. This thesis hypothesises that side-effects 
are due to localised perfusion deficits arising from high local interstitial 
pressures within the infused brain. A method of quantitative imaging is 
described that could lead to a better understanding of this process. On the 
basis of this work recommendations are made about how a minimally 
symptomatic infusion could be achieved and how this could be important 
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Chapter 1. Introduction 
 
Bypassing the blood brain barrier to improve outcomes for sick children   
Children with neurological disease have significantly longer hospital stays and incur 
double the costs compared to children with diseases outside the nervous system 
(Moreau et al. 2013). Outcomes for many neurological conditions have failed to 
improve over the time, with paediatric brain cancer being the obvious example.  By 
comparison, acute lymphoblastic leukaemia was once fatal, but now 90% of those 
diagnosed in childhood will survive longer than 5 years (Oliver et al. 2014). Yet, brain 
tumours represent the greatest cancer killer of children, representing the third most 
common cause of death overall (Ostrom et al. 2014). Around 70% of children are 
expected to survive over 5 years but outcomes have not significantly changed in the 
past 20 years (Smith et al. 2010).  Developing treatments that access the brain and 
manipulate underlying pathophysiology remain a major hurdle to improving 
outcomes for patients with both cancerous and non-cancerous diseases of the 
central nervous system (CNS). 
Normal brain function is dependent on optimal neuronal activity, which in turn is 
dependent on a tightly controlled microenvironment, which is protected from the 
chemical fluctuations in the systemic circulation. This is achieved by the blood brain 
barrier (BBB). As reviewed by Ribatti et al., 2006, the concept of a barrier between 
the blood and the brain has been around for over 300 years. The first suggestions 
were documented in the 17th century after it was found that systemic administration 
of wax and mercury failed to penetrate nervous tissue. 200 years later, Paul Ehrlick 
in the late 19th century discovered that all organs bar the brain and spinal cord 
became stained after peritoneal injection of tryptan blue. His student, Edwin 
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Goldmann, then reversed this experiment by injecting dye into the cerebrospinal fluid 
- successfully staining the brain and spinal cord but sparing the rest of the body. This 
clearly demonstrated the compartmentalisation between the body and central 
nervous system (CNS). Max Lewandowsky in 1900 concluded, from his experiments 
with cholic acids and sodium ferrous cyanide, that ‘the walls of cerebral capillaries 
hinder the transit of certain compounds’. This led to an explosion of research 
marking the beginning of the BBB as we know it. We now understand that barriers 
protecting the brain go beyond the blood-brain interface and they include:  
1. The BBB between the brain and cerebral blood vessels  
2. The embryonic CSF-brain barrier between the ventricular system and the          
extracellular fluid of the brain  
3. The blood-cerebral spinal fluid (CSF) barrier between the brain and choroid 
plexus epithelial cells  
4. The arachnoid barrier between the CSF and the dura mater 
 
Nevertheless, the most important barrier in the treatment of neurological disease is 
BBB, which accounts for the 15-25 m2 of brain-body interface (Wong et al. 2013). In 
the 1950s, it was recognised that the lipid molecules were more amenable to transit 
across the BBB than water-soluble, highly charged or protein-bound molecules 
(Davson and Smith 1957). In 1967, descriptions of the BBB as a physical barrier 
became apparent following the introduction of electron microscopy. This allowed the 
description of the BBB ultra-structure for the first time, including the presence of 
tight-junctions between brain endothelial cells and the absence of intracellular 
pinocytic vesicles and fenestrae (Reese and Karnovsky, 1967). A principle 
component of the BBB is the neurovascular unit, which maintains the BBB via a bi-
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directional relationship between brain endothelial cells and surrounding glia, 
microglia, neurons, pericytes, mast cells and other immune cells (Hawkins and Davis 
2005). As reviewed by Banks, 2016, passage of molecules across this barrier can be 
co-ordinated by: 
 
 immune-active molecules released by immune cells, supportive cells such as 
glia or astrocytes or by the barrier cells themselves  
 trans-endothelial passive diffusion depending on its charge, lipid-solubility, 
hydrogen bonding and molecular size  
 transporters that can actively move molecules as part of an energy dependent 
process, or facilitate diffusion down a concentration gradient 
 glycoprotein binding that can move highly charged molecules during 
adsorptive transcytosis 
 specialised differential functions of the luminal and ad luminal surfaces of the 
bi-lipid membrane 
 
Pharmacological exploitation of each of these functions represents a promising 
avenue for drug development. The most obvious pharmacological solution to 
increasing the concentration of drug in the brain is to increase the concentration 
administered. High dosing is widely used in clinical practice to treat CNS disease, 
notably in the treatment of haematological malignancies, but its major limitation is the 
associated systemic toxicity (Tetef et al., 2000). Other pharmacological solutions of 
bypassing the BBB remain experimental. Examples include sequestering drugs in 
the brain by blockade of drug efflux mechanisms (Wong et al., 1993) encapsulation 
of drugs within transportable nanoparticles (reviewed by Masserini, 2013) and 
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combination of systemic administration with BBB disruption techniques using 
focused ultrasound (Lui et al, 2010).  However, all these approaches still require 
systemic exposure to the drug and/or the drug vehicle and depend on efficient 
penetration of the BBB, which remains a highly sophisticated guardian of the brain-
blood interface.  
 
Another approach to access the brain more effectively is to change the route of 
administration and this can be achieved in a variety of ways. Intra-nasal delivery of 
insulin has been used to enhance memory function in patients with Alzheimer’s 
disease (Reger et al., 2000). This route exploits the connections between the intra-
nasal cavity with the cerebrum and brain stem via the olfactory and trigeminal nerves 
(reviewed by Crowe et al, 2018). Intra-thecal administration is a well-recognised 
route used in anaesthesia, chronic pain management, spasticity and delivery of 
chemotherapy for some cancers (Deer, 2001; Penn, 1985; Ruggerio, 2001). 
However, the use of intra-thecal delivery is constrained by practical limitations of 
accessing the CSF, risks of introducing highly neurotoxic drugs to the CNS and the 
inability to treat deep-seated intraparenchymal disease (Blayney et al., 1995; Larson 
et al., 1971; Poplack et al., 1980). Drug-impregnated media can also be applied 
locally at surgery. Wafers impregnated with 1,3-bis (2-chloroethyl)-1-nitrosourea 
(Gliadel®) can be used to line the resection cavity following glioblastoma multiforme 
(GBM) surgery and have been shown to increase survival from 11.6 months to 13.9 
months (Westphal et al., 2003). Similarly, mouldable polymers loaded with etoposide 
and methotrexate have also been used to control local disease within the tumour bed 
(Rahman et al., 2013). Intra-arterial drugs can be used and have the benefit of not 
requiring surgical access. It has been used in a variety of diseases including brain 
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cancer, large vessel stroke and delayed cerebral ischaemia following subarachnoid 
haemorrhage (Joshi et al., 2015; Furlan et al., 1999; Hollingworth et al, 2015). It is 
performed by cannulation of the carotid or vertebral arteries via peripheral arteries 
such as the femoral or radial artery. Intra-arterial drug embolization aims to exploit 
the brain’s capillary networks to reach the target site where diffusion distances are 
relatively short (Joshi et al., 2008). However, such therapy has failed to reach 
mainstream clinical practice likely owing to concerns about cerebrovascular injury, 
the absence of clinical evidence to demonstrate superiority over intra-venous 
delivery and the expense and availability of endovascular services (Joshi et al., 
2008).  
A limitation of these treatments is that after bypassing the BBB ongoing drug 
distribution depends on passive diffusion (Lieberman et al. 1995). This can result in 
small heterogeneous treatment volumes and suboptimal local disease control (Barua 
et al., 2014). Homogenous drug distribution through large brain volumes can be 
achieved using convection enhanced delivery (CED) (Bobo et al., 1994). CED refers 
to intra-parenchymal pressure-driven infusion that establishes a pressure gradient at 
the tip of an intra-parenchymal catheter; this creates a convection current within the 
brain interstitium. Drug then displaces extra-cellular fluid by bulk flow through a 
volume of distribution several times greater than the volume of infusion, which 
enables delivery of drug through clinically-relevant brain volumes (Bienneman.et al., 
2012).  
CED has been widely used pre-clinically since the early 1990s (Bobo, 1994) but its 
failure to translate into clinical practice is dependent on several factors that 
determine therapeutic efficacy.  These include characteristics of the drug and the 
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performance of the drug delivery device itself, which in turn is dependent on the 
design of the drug delivery system and its optimal surgical implantation (Lewis et al., 
2016). 
CED aims to displace extra-cellular fluid - consisting of dissolved anions, cations and 
extracellular matrix proteins - and replacing it with the therapeutic agent of choice. 
This model of drug delivery is subject to different principles that govern conventional 
drug design. In conventional drug design, once a drug has been found to act on a 
validated target, assays are used to optimise the drug for clinical application. Key 
tests include measurement of lipophilicity to ensure movement across membranes, 
metabolic stability to predict liver clearance, interaction with key enzymes such as 
CYP450 and intestinal absorption (Hughes et al., 2011). If drugs were optimised this 
way for delivery by CED, highly lipophilic drug would be rapidly cleared from the 
brain and the direct administration and minimal systemic exposure would render 
considerations regarding absorption, first and second pass metabolism and CYP450 
enzyme interference almost irrelevant.  
The ideal drug for CED should be water-soluble, freely distribute in the brain 
interstitium, maintain a long tissue half-life and should be non-toxic to normal brain 
parenchyma (Barua et al., 2012).  Before drugs are infused into the brain, the drug 
must be dissolved in media that is non-toxic, which can be fully resorbed to prevent 
permanent damage to the interstitium. The drug and its excipients must also remain 
in solution at physiological pH and temperature to prevent precipitation of drug within 
the interstitial space, which could cause cellular damage and impair of drug 
distribution. The drug must be able to flow freely within the interstitium to maximise 
the volume of distribution, which is influenced by several factors. Positively charged 
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drug molecules bind to cellular membranes impeding drug distribution and so using 
neutral or negatively charged drug molecules are best suited to administration by 
CED (Saito et al. 2006; Kikuchi et al. 2008). Increasing infusate viscosity can help to 
increase the efficiency of distribution (Perlstein et al., 2008).  Molecules that have 
affinity for extracellular matrix proteins also limit distribution. For example, adenoviral 
vectors have heparin binding regions and hence co-infusion with heparin helps to 
saturate extra-cellular matrix heparin sulphate molecules and aid distribution 
(Hamilton et al. 2001). These factors must all be considered to maximise the efficacy 
of drug distribution in CED.  
The drug itself must also be non-toxic to underlying normal parenchyma. This can be 
problematic in the setting of oncology whereby the infusates are intended to kill 
cancerous cells and can also damage underlying brain and consequently limit the 
volume of infusion. Vincristine, for example, is highly neurotoxic and lethal following 
intrathecal administration despite being an effective anti-cancer agent when 
delivered systemically (Manellis et al., 1982). Therefore, drugs delivered by CED 
must distribute efficiently, avoid rapid clearance from the CNS and be therapeutically 
efficacious without causing irreversible damage to the underlying parenchyma. 
Hence, extensive preclinical testing of drug stability, tissue half-life, distribution 
characteristics and toxicity profiles in clinically relevant preclinical models must be 
performed before drugs can be administered by CED in humans.   
Controlling drug distribution is essential to achieve therapeutic efficacy. In CED, 
regardless of how ideal the drug characteristics may be, any brain volume outside 
the volume of distribution cannot be feasibly treated. In the PRECISE study (Kunwar 
et al., 2013), 192 patients with recurrent GBM were randomised to receive IL13-
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PE38QQR administered by CED using between 2 and 4 intraparenchymal catheters. 
There was no improvement in overall survival compared to patients treated with 
Giadel ® wafers. A reason for this failure has been attributed to inadequate coverage 
of the target volume (Sampson et al., 2010). Achieving adequate coverage within the 
target volume is undermined by reflux/back flow along the catheter trajectory away 
from the catheter tip. This phenomenon can result in variable pressure gradients and 
thereby reducing the efficiency of CED (Bobo et al., 1994). Factors that are 
understood to increase catheter reflux are: 
 
 Large catheters, which increase the surface area and reduce resistance for 
drug reflux (Morrison et al. 1999, Chen et al. 1999, White et al. 2011) 
 High infusion rates (Chen et al. 1999) 
 Local tissue trauma (White et al. 2011) 
 Slower catheter insertion times  (Casanova et al., 2014) 
 
Various catheter designs have been developed to control reflux (Figure 1.1), 
reviewed by Lewis et al., 2016. Step-design catheters, which are tapered toward the 
end, demonstrate superior reflux control. The exact mechanism behind this is 
unknown. The recessed-step catheter design, used by the Function Neurosurgery 
Group, is a further iteration of this and consists of a catheter housed within an inner 
and outer guide tube (Figure 1.1). The inner guide tube is recessed within the outer 
guide tube and is thought to control reflux by creation of a tissue seal at the interface 
of the catheter and guide tube (Gill et al., 2011). This catheter design has been used 
to deliver drugs to patients with Diffuse Intrinsic Pontine Glioma (DIPG) (Barua et al., 
2013), GBM (Barua et al., 2016) and Parkinson’s Disease (Whone et al., 2019).  
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Figure 1.1. Convection enhanced delivery catheter designs. End Port Cannula (A), 
Multi-Port Cannula (B), Porous Tipped Catheters (C), Balloon Tipped Catheters (D) 
and Stepped Profile Catheters (E). A recessed stepped catheter design used by the 
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Diffuse Intrinsic Pontine Glioma and Convection Enhanced Delivery 
 
DIPG is a rare and lethal disease of middle childhood. The median survival is 11.1 
months whilst progression free survival is 6 months (Veldhuijzen van Zanten et al., 
2017). Patients typically present with a “classical triad” of ataxia, cranial neuropathy 
and long tract signs (Johung and Monje, 2017). Initial diagnosis involves magnetic 
resonance imaging, at which point parents are given a terminal diagnosis and 
recommendations for treatment and palliative care should be made simultaneously 
(Veldhuijzen van Zanten et al., 2017). Radiotherapy is the mainstay of treatment, 
which is given upfront. There is no evidence to suggest survival is better with high 
dose radiotherapy (78Gy) versus conventional doses (54 Gy) (Packer et al., 1994). 
Indeed, there is evidence to suggest that hypofractionated doses (34 Gy) achieve 
similar outcomes (Zaghloul et al., 2014). In some cases, a survival benefit can be 
achieved in patients who are re-irradiated at first progression, however, this cannot 
feasibly be offered to some patients (Janssens et al., 2017).  Many trials have 
explored the role of chemotherapy; however, none have been shown to significantly 
improve survival (Hargrave et al., 2006).  
 
The location of the tumour is the most important determinant of its severe 
neurological burden.  The pons, which means ‘bridge” in Latin, resides between the 
cerebellum, the cerebrum and spinal cord as the central component of the brainstem. 
It contains crossing cerebellar fibres, descending corticospinal fibres, ascending 
sensory pathways, trigeminal, abducens, facial, vestibular and acoustic nuclei 
(Figure 1.2). The dorsal pons forms the floor of the fourth ventricle. Consequently, 
disease arising within the pons can cause profound neurological disability and 
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obstructive hydrocephalus due to invasion to these vital intrinsic structures or 
blockage and CSF flow. 
 
Figure 1.2. A cross-section of the pons at the level of the trigeminal nerve nucleus. 
Adapted from Gray's Anatomy (1958) 
 
Disease progression is associated with severe neurological disability. The most 
common symptoms in end stage disease include impaired mobility, dysphagia and 
dysarthria, with some children developing locked in syndrome with total paresis and 
the inability to speak or swallow (Veldhuijzen van Zanten et al. 2015; Masuzawa et 
al., 1993). Consequently, the young age at diagnosis, the lack of treatment options, 
the rapid progression toward severe disability and death render DIPG a particularly 
cruel disease. 
 
However, despite the bleak outlook, DIPG is poised for progress (Warren, 2012). For 
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a long time, progress in DIPG research has been stunted by a lack of available 
tissue for research (Louis et al., 1993; Cheng et al., 1999; Gilbertson et al., 2003). 
The neurological morbidity of brain stem biopsy and development of magnetic 
resonance imaging meant that for a time DIPG became a radiological diagnosis. 
However, with increasing capabilities to perform genomic analysis on biopsy 
samples and identify druggable targets, there is an appetite for the return of 
brainstem biopsy (Kieran et al 2015; Rutka 2012; Macdonald et al., 2012). Through 
collaborative biological and genomic studies, it is now understood that DIPGs are 
distinct from adult high-grade gliomas and supratentorial paediatric high-grade 
gliomas (Mackay et al., 2017). DIPG possesses significant intra-tumoural 
heterogeneity consisting of different tumour subpopulations that contribute to 
tumour-genicity and treatment resistance (Vinci et al., 2018).  Indeed, it has been 
demonstrated that DIPG is characterised by K27M mutations in H3 genes, H3FA and 
the HIST1H3B (Wu et al., 2012; Quong-Quang et al 2012; Schwartzentruber et al 
2012). This has led to the reclassification of DIPG as Midline Diffuse Glioma 
H3K27M by the World Health Organisation (Louis et al., 2016). This reclassification 
groups DIPG together with midline tumours bearing the same type of mutation 
located outside the pons, often in the thalamus. It is hoped that drugs that will be 
designed to functionally target these mutations and will lead to better outcomes for 
patients. Indeed, genetic classification may lead to different treatment strategies 
appropriate to their risk profile. Medulloblastoma has been reclassified based on 
molecular profiles (Northcott et al, 2011), with low risk subtypes being subjected to 
trials comparing reduced intensity treatment strategies versus standard therapy 
(NCT02724579; ANCNS1422).  Nevertheless, the association between genetic 
subtypes and prognosis strongly suggest that H3K27 mutations are closely related to 
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clinically relevant disease behaviour. But despite, the therapeutic potential of 
molecular phenotyping, DIPG is still a useful term. Even amongst H3K27M Midline 
Diffuse Gliomas, the outcomes of brainstem tumours are still poorer than their supra-
tentorial counterparts (Mackay et al., 2017), suggesting that there are factors beyond 
genetics that are still important. Indeed, it is likely that that much of this lethality of 
DIPG compared to many supratentorial high grade gliomas is their anatomical 
location.  
 
Chronic intermittent convection enhanced delivery in DIPG and the Functional 
Neurosurgery Group 
 
Despite the hopes surrounding targeted therapy, penetrating the BBB still remains a 
hurdle for any new drug intended to treat DIPG and wider CNS disease. CED has 
become an important avenue for exploration for the future of DIPG. Several trials are 
underway (NCT03086616; NCT03566199; NCT01502917). The only trial published 
to date using CED in DIPG is a landmark phase I dose escalation study delivering an 
124I isotope conjugated to an antibody targeting B7-H3 antigen found on DIPG cells 
(Souweidane et al., 2018). The study reported findings from 28 patients and 
demonstrated the principle of using CED to achieve high intra-lesional dosing with 
negligible systemic exposure. In this trial between 0.24 and 4.4 mL were infused 
over 1.18 -16 hours. Of the 25 who reached the primary end point of the study, 25 
patients had a median overall survival of 15.3 months. The treatment was tolerated; 
however, there were 275 all cause adverse events, which emphasizes the need to 
better understand how morbidity can be reduced. Most events were mild to moderate 
(251/271). Using Common Terminology in Criteria for Adverse Events (CTCAE 
Version 5.0) the most common adverse events were hyperglycaemia, reduced 
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lymphocytes and decreased white blood cells reported in 27, 24 and 19 instances 
respectively. There was one instance of life threatening respiratory failure. A 
limitation of the CTCAE in describing toxicity arising from brain stem CED is that is 
has been designed to evaluate systemic therapy and does not emphasize the 
importance of anatomical targeting, which is central to CED.  
 
When adverse events are grouped together by system adverse events were 
commonly neurological, which were reported in 69 instances - accounting for 25% of 
total adverse events recorded (Figure 1.3). Furthermore, when it is considered that 
the brain stem controls cardiovascular and respiratory functions, as well as housing 
various essential neural structures, it is evident that even more adverse events could 
be attributed to brain stem dysfunction as a whole (Figure 1.3). Indeed, some 
recorded side-effects could also be due to combinations of neurological deficits such 
as dysarthria arising from bulbar dysfunction or cerebellar dysfunction. This is less 
important when evaluating systemic therapy because delivery to the brain will be 
assumed to be uniform. When we consider the interaction between brain-
architecture, drug concentrations, local tissue pressures and surgical injury these 
distinctions become important to understand and prevent toxicity. Moreover, a 
significant part of the complex neurology recorded could be due to disease 
progression, the extent to which the CTCAE can differentiate between treatment-
related neurological deterioration and disease-related deterioration is limited. 
Development of the technique requires a better understanding these problems and 
how their impact can be mitigated, which may involve a revision of how we describe 














































































































































Figure 1.3. Grouping of adverse events reported in the Convection-enhanced 
delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, 
Phase 1 trial (Souweidane et al., 2018).   Adverse events are grouped based on 
system affected, demonstrating that neurological side-effects account for a 
significant proportion of morbidity (A). Adverse events attributable to brain stem 
function are further described, demonstrating the complex neurological phenotype 
of patients with DIPG receiving CED (B) 
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Another consideration regarding work by Souweidane et al., 2018 is that this method 
of delivery can only be used on a limited number occasion, usually only once. This 
technique suits the infused agent, which uses a antibody-conjugated isotope, which 
has a long half-life and prolonged radio-sensitizing effect. When using a 
pharmacological agent, such as the many proposed targeted therapies for DIPG, it 
would advantageous to perform intermittent delivery so high intra-parenchymal 
concentrations of drug can be maintained for longer. The first attempts to treat DIPG 
with intermittent CED by the Functional Neurosurgery Group at the University of 
Bristol involved stereotactically implanting a guide tube into the pons, which allowed 
repeated access the pons via the same trajectory (Barua et al., 2013). Prior to each 
infusion, the drug delivery catheter would be inserted through the guide tube to 
target. The distal catheter would be tunnelled out through the skin and connected to 
a drug administration pump allowing pontine infusion in the awake patient.  When 
infusion was completed the drug delivery catheter would be removed during a short 
operation. When the patient had recovered from pontine infusion the pons could then 
be re-accessed via the indwelling guide tube. This method enabled repeated delivery 




Figure 1.4. Intermittent convection enhanced delivery in a patient with diffuse 
intrinsic pontine glioma using an indwelling guide tube. A recessed-stepped catheter 
system would be inserted stereotactically into the tumour leaving behind the outer 
guide tube (A). At infusion, a catheter would be inserted to target and the distal 
catheter would be tunnelled through the scalp and connected to an external infusion 
pump (B). Adapted from Barua et al. 2013 
 
However, this approach was limited by the need for two operations for each pontine 
infusion and the repeated catheterisation of the brain stem. This would increase the 
risk of surgical complications and reactive gliosis around the catheter track, which 
could impair drug distribution. To overcome these limitations a chronic intermittent 
CED system using a transcutaneous bone-anchored port (TBP) was developed in 
large animals before being translated into humans with GBM and Parkinson’s 
Disease (Bienneman et al., 2012; Barua et al., 2016; Whone et a., 2019). This drug 
delivery system was adapted for use in DIPG using a system of 4 implantable micro-
catheters, targeting the pons via trans-frontal and trans-cerebellar trajectories 
connected to the TBAP by sub-galeal tubing. Initially, 8 patients (ages 4–12 years) 
with DIPG were infused with up to 9 cycles of carboplatin divided over two 
consecutive days at a concentration of 0.18 mg/ml (Singleton et al. 2016). These 
infusions were associated with neurological side effects, which were most commonly 
reported during the first cycles. This thesis describes the ongoing development of 
A B 
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this technique using sodium valproate, as a targeted therapy for DIPG (Killick-Cole et 
al., 2017), as a single therapy and in combination with carboplatin in 15 children 
treated on compassionate grounds. 
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Table 1. 1. All cause adverse events from Convection-enhanced delivery for diffuse 
intrinsic pontine glioma: a single-centre, dose-escalation, Phase 1 trial using the 






Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 
Abducens palsy* 3 (11%) 0 0 0 
Agitation* 2 (7%) 2 (7%) 0 0 
Alanine aminotransferase increase 9 (32%) 0 0 0 
Anaemia 3 (11%) 6 (21%) 0 0 
Ankle clonus* 3 (11%) 0 0 0 
Anxiety 2 (7%) 2 (7%) 0 0 
Aspartate aminotransferase increase 5 (18%) 2 (7%) 0 0 
Ataxia* 7 (25%) 0 1 (4%) 0 
Cough 3 (11%) 0 0 0 
Decreased rapid alternating movements* 3 (11%) 0 0 0 
Diplopia* 6 (21%) 1 (4%) 0 0 
Dysarthria* 3 (11%) 0 1 (4%) 0 
Dysmetria* 5 (18%) 0 0 0 
Dysphagia* 2 (7%) 1 (4%) 0 0 
Facial palsy* 9 (32%) 1 (4%) 0 0 
Fatigue 3 (11%) 0 0 0 
Gait disturbance* 4 (14%) 1 (4%) 0 0 
Headache* 8 (29%) 6 (21%) 0 0 
Haemoglobin increased 5 (18%) 0 0 0 
Hyperglycaemia 17 (61%) 10 (36%) 0 0 
Hypernatraemia 6 (21%) 0 0 0 
Hypertension 3 (11%) 2 (7%) 0 0 
Hypoalbuminaemia 17 (61%) 0 0 0 
Hypocalcaemia 4 (14%) 0 2 (7%) 0 
Hypokalaemia 4 (14%) 0 3 (11%) 0 
International normalised ratio increased 10 (36%) 0 0 0 
Lymphocyte count decreased 5 (18%) 9 (32%) 10 (36%) 0 
Muscle weakness, left-sided* 4 (14%) 1 (4%) 1 (4%) 0 
Muscle weakness, right-sided* 3 (11%) 1 (4%) 2 (7%) 0 
Nasal congestion 5 (18%) 1 (4%) 0 0 
Neutrophil count decreased 7 (25%) 8 (29%) 0 0 
Nystagmus* 3 (11%) 0 0 0 
Pain 6 (21%) 3 (11%) 0 0 
Paraesthesia 3 (11%) 0 0 0 
Platelet count decreased 7 (25%) 0 0 0 
Rash, maculo-papular 2 (7%) 1 (4%) 0 0 
Respiratory failure 0 0 0 1 (4%) 
Skin infection 1 (4%) 0 1 (4%) 0 0 
Vomiting 3 (11%) 2 (7%) 0 0 
White blood cells decreased 13 (46%) 6 (21%) 0 0 




Chapter 2. The treatment of patients with sodium valproate 
administered by chronic intermittent convection enhanced 




Around 80% of diffuse intrinsic pontine glioma (DIPG) possess mutations in genes 
encoding histone proteins (Wu et al. 2012, Schwartzentruber et al. 2012, Khuong-
Quang et al. 2012, Sturm et al. 2012), Histones are proteins that form nucleosomes 
packaging deoxy-ribonucleic acids (DNA) into chromatin. Histones belong to five 
major subgroups, H1/5, H2A, H5 and H3, the latter of which is encoded by genes 
HIST1H3B or H3F3A and are mutated in DIPG (Wu et al. 2012, Schwartzentruber et 
al. 2012, Khuong-Quang et al. 2012, Sturm et al. 2012). Histone proteins bind 
together to form octameric complexes and undergo epigenetic modification to control 
gene expression (Lorch, LaPointe and Kornberg 1987). Epigenetic modification of 
histones is dependent on the enzymatic addition and removal of chemical groups - a 
process known as covalent modification. This becomes heavily dysregulated in DIPG 
(Lewis et al. 2013, Bender et al. 2013). Therefore, a possible strategy to improve 
outcomes for patients with DIPG is to functionally target disordered epigenetic 
regulation (Grasso et al. 2015). An important group of enzymes involved in covalent 
modification of histones are histone deacetylases (HDAC), which remove acetyl 
groups from histone lysine residues.  As reviewed by Glozak and Seto, 2007, this 
process can neutralize positive charge to relax chromatin structure and increase 
bromodomains to activate gene transcription. HDACs have numerous roles in 
oncogenesis including inhibition of transcription in favour of proliferation, repression 
of pro-apoptotic factors and inhibition of cell cycle check-point molecules. Grasso et 
al., 2015 demonstrated that Panobinostat, as an FDA-approved pan-HDAC inhibitor 
 34 
(HDACi), was a potent agent against DIPG cells in vitro and in rodent xenografts. 
Panobinostat is now subject to an ongoing clinical trial (NCT02717455).  
 
However, other inexpensive drugs currently in clinical use also have HDACi 
properties including anti-epilepsy drug, sodium valproate. The HDACi characteristics 
of sodium valproate give rise to its teratogenic properties in pregnancy and also its 
anti-cancer activity (Phiel et al. 2001, Brodie and Brandes 2014). Patients with DIPG 
treated for seizures with sodium valproate have been shown to survive longer (Felix 
et al. 2011, Felix et al. 2014, Masoudi et al. 2008). However, like many drugs, 
sodium valproate penetration into the central nervous system is limited and reduces 
intra-tumoural concentration. It is estimated that only between 6% and 20% of the 
sodium valproate serum concentration is found in the brain parenchyma (Vajda et al. 
1981, Kim et al. 2013, Wieser, 1991). Increasing systemic administration may 
overcome such a problem; however, at high doses sodium valproate causes 
drowsiness, mood disturbance, thrombocytopenia, bone marrow suppression, weight 
gain and hair loss (Sztajnkrycer, 2002). In order to achieve high intra-tumoural 
concentration and reduce systemic toxicity, local delivery of sodium valproate using 
CED may be advantageous. Sodium valproate is water soluble and readily 
compatible with CED. We hypothesised that sodium valproate could be delivered by 
chronic intermittent CED to provide local control of disease. We tested this 
hypothesis in a convenience pilot cohort of children with DIPG treated on 





Patients were referred internationally from paediatric oncology centres. Patients 
were offered treatment with sodium valproate CED as a single agent on 
compassionate grounds if they were considered eligible. Eligibility was determined 
on the basis of the patient’s clinical status, radiological signs consistent with DIPG 
and a total disease burden confined to the brainstem within a volume coverable by 
two trans-frontal and two trans-cerebellar catheters. Patients of poor clinical status, 
metastatic disease or with cysts and haemorrhage obstructing catheter implantation 
were not offered treatment. 
 
Ethics and consent 
Implantation of the drug delivery system was approved by the Medical and 
Healthcare products Regulatory Agency. Treatment with chronic intermittent CED, 
including implantation of the drug delivery system and brain stem infusion, was 
subject to local independent ethical approval at the University Hospital Bristol NHS 
Trust and Harley Street Clinic. Parents were consented for the experimental nature 
of the treatment including potentially unpredictable and severe complications.  
 
Drug delivery system implantation 
Patients underwent magnetic resonance imaging (MRI) under general anaesthetic to 
allow planning of catheter trajectories and the transcutaneous bone anchored port 
(TABP). Drug delivery system implantation was planned using an in-house module of 
neuro|inspire® neurosurgical planning software (Renishaw, Wooton-under-Edge) as 
follows: 
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 the tumour boundary was traced using fluid attenuated inversion recovery 
(FLAIR) imaging 
 Bilateral trans-frontal and trans-cerebellar trajectories were planned to target 
the ventrolateral pons and the central/dorsal pons respectively avoiding blood 
vessels 
 Step-length from the catheter outer guide tube was increased to 35mm or the 
grey-white matter interface, whichever smallest 
 Recess step between the inner and outer guide tube was 10 mm. 
 The TBAP was planned in the parietal bone superior to the asterion 
 
The method of implanting the drug delivery system has been previously described 
(Barua et al. 2016).  In short, patients would be placed under general anaesthetic 
and their head fixed in Leksell® stereotactic frame. The patient would undergo pre-
operative computer tomography (CT) angiogram, which would then be co-registered 
to the pre-operative MRI using neuro|inspire® software. The patient would be placed 
prone with the Leksell frame fixed to the neuro|mate® stereotactic robot (Renishaw 
Plc; Figure 2.1). After necessary sterile precautions and administration of antibiotics, 
stereotactic co-ordinates would then be exported to the stereotactic robot to execute 
the first trajectory. Here, a scalp incision would be made and the periosteum 
retracted, a multi-featured burr hole would be drilled. Using a specialised suite of 
instruments, a 1 mm guide rod would be passed along the trajectory to breach the 
grey/white interface. A guide rod with an outer diameter of 0.6 mm would then be 
passed to target. A recessed-step catheter system (Figure 2.1) would then press fit 
into the multi-featured burr hole followed by a stylet to keep the catheter tract patent. 
This would be repeated for each trajectory followed by implantation of the TBAP. The 
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TBAP would be sited through a hole punched in the skin, subcutaneous tissue would 
be excised using a surgical aspirator preserving the underlying periosteum. Around 
the hole a semi-circular flap would be raised with the base of the flap sparing the 
occipital arteries. The skull would then be drilled to accommodate the TBAP. After 
this, the TBAP, would be connected to a tubing manifold, which would then be 
connected to subgaleal tubing. Subgaleal tubing would be tunnelled to the respective 
catheters and primed with artificial cerebral spinal fluid (aCSF). Four carbothane 
catheters would be cut to length and each connected to a subgaleal tube. These 
would be inserted to target whilst infusing aCSF. Once in place, the subgaleal tubing 




Pontine infusion was initiated within 72 hours of implantation of the drug delivery 
system. Prior to infusion patients would undergo pre-infusion MRI to exclude contra-
indications such as brainstem haemorrhage or hydrocephalus. Patients were 
examined by the attending neuro-oncologist. Consent for infusion would be gained 
from the parent or guardian. Pontine infusion would be conducted in the Paediatric 
Intensive Care Unit (PICU). A needle administration set would be connected to 
extension lines, which were connected to an external B-Braun pump (Figure 2.1). 
The lines would be primed with drug and attached to an actuator base. The base 
would be applied to the TBAP, all catheters would be infused starting with a ramping 
regime as follows: 
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 0.03ml/min/catheter for 10 min,  
 0.06 ml/hour/catheter for 5 min,  
 0.12 ml/min/catheter for 5 min,  
 0.18 ml/min/catheter for 5 min,  
 0.18-0.3 ml/min/catheter until completion  
Infusion would be stopped at the onset of significant neurological deficit according to 
the attending paediatric neuro-oncologist/neurosurgeon. 10 patients were treated 
(Patients A-J). Sodium valproate was delivered in Patient A at 14.4mg/ml before 
being escalated to 28.8 mg/ml after the first infusion. Infusions were conducted at 
28.8mg/ml thereafter. Patient D received sodium valproate at 21.6mg/ml due to 
concerns about concentration related toxicity. 
Pontine Infusions were conducted over two consecutive days as part of a single 
treatment cycle. Treatment cycles were repeated at 4-8 week intervals depending on 




Figure 2.1. A robot-guided chronic, intermittent drug delivery with a transcutaneous 
bone anchored port (TBAP) for awake pontine infusion. A. neuro|inspire® 
neurosurgical planning software (Renishaw, PLC, Wooton under Edge), is used 
alongside the Neuro|mate stereotactic robot (Renishaw PLC) to site the drug delivery 
system according to pre-operative imaging (Barua et al. 2013); B. A recessed 
stepped catheter system using an inner and outer guide tube is inserted into the 
brain to facilitate controlled reflux and aid homogenous drug distribution (Barua et al. 
2013);  C. Schematic diagrams of the drug delivery system in situ, consisting of skull 
anchored catheters, subgaleal tubing connected to a manifold and TBAP, which 
allows the connection of an administration set; D. The TBAP in situ in an adult 
patient (Barua et al. 2016a); E. Child-friendly diagram of awake pontine infusion via 
the chronic, implantable drug delivery system, courtesy of Harley Street Clinic, 








10 patients with DIPG were accepted for drug delivery system implantation and 
treatment with sodium valproate monotherapy delivered by CED (Table 2.1). 3 
patients had DIPG with confirmed H3K27M DIPG. All patients, except Patient E 
received radiotherapy prior to implantation. Patient C received proton beam therapy 
and Patient D had hypo-fractionated radiotherapy. In addition to CED, patients also 
received a variety of additional experimental treatments (Table 2.1). Patients were 
implanted at a median of 4.6 months (range 3.3-10.1 months) following diagnosis.  
Surgical implantation of the drug delivery system was well tolerated by all patients 
except Patient E. Patient E was implanted prior to radiotherapy. This patient had 
H3K27M positive midline diffuse glioma and was implanted 3.6 months following 
diagnosis. The implantation was complicated by intra-operative extubation and 
hypertension. Post-operatively, the patient had generalized brain oedema with micro-
haemorrhage away from the catheter trajectory resulting in neurological deterioration 
requiring hypertonic saline. Her clinical status contraindicated further pontine infusion. 
The patient improved over the intervening 2 weeks and she began radiotherapy 2 
weeks later. After 3 fractions of radiotherapy at 1.8 Gy, the patient was re-
anaesthetised for an unrelated urological procedure but sustained another period of 
intra-operative hypertension and suffered brain stem haemorrhage. Patient E died 
4.1 months from diagnosis.  
 
Pontine infusions were associated with neurological deterioration. Patient A 
developed left facial weakness during her first infusion, which recovered immediately 
upon stopping the infusion suggesting it was directly infusion-related. Review of 
catheter position demonstrated that the right frontal catheter terminated deep to the 
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left facial colliculus. This catheter was retracted and further infusions were 
associated with less severe facial weakness. Each subsequent infusion was 
associated with mild-moderate cerebellar symptoms, mild right-sided hemiparesis 
and left 6th nerve palsy, all of which recovered between cycles. Unlike the initial facial 
palsy, these deficits could not be ascribed to a specific catheter. Subsequent 
patients who received sodium valproate by CED also developed neurological 
symptoms during infusion, which included hemiparesis, cerebellar ataxia, trigeminal 
dysesthesia, facial nerve and abducens nerve palsies. Most neurological deficits 
recovered. Patent B suddenly deteriorated at the beginning of infusion requiring 
cessation of infusion and immediate CT imaging. There was no evidence of acute 
intracranial event such as hydrocephalus or brain stem haemorrhage. The patient 
went onto make a slow recovery but remained wheelchair bound thereafter. Patient 
D suffered left sided hemiparesis repeatedly during infusions and after the second 
infusion failed to recover to pre-infusion baseline. Patient D went onto receive a 
lower concentration of sodium valproate at 21.6mg/mL; however, this was 
associated with a similar side-effect profile. Patient F also developed ataxia during 
infusion, which also failed to return to baseline following infusion.  
Median overall survival from diagnosis was 14.4 months (range 4.1 - 23.6).  
Response following treatment with sodium valproate by CED was observed in 
Patient A after 2 cycles of CED (Figure 2.2). However, at 13.3 months following 
diagnosis, MRI demonstrated evidence of progressive disease. The patient was 
referred for palliative radiotherapy followed by a final cycle of CED at 18 months. At 
19 months, the patient rapidly deteriorated and died, 20 months after diagnosis. 
Patients C, F G and H developed progression of disease within 2 months of 
receiving CED. Due to the observed lack of efficacy in these cases, patients still 
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receiving treatment were switched onto sodium valproate therapy combined with 




Figure 2.2. Chronic intermittent convection enhanced delivery of sodium valproate for the 
first in human treatment of diffuse intrinsic pontine glioma (Patient A). Pre-implantation 
axial Fluid Attenuated Inversion Recovery (FLAIR) sequences along the planned 
trajectory of the left cerebellar catheter (yellow) demonstrated pre-implantation (A). Post-
operative imaging demonstrates implantation of a chronic implantable drug delivery 
system connecting a bone-anchored drug administration port to 4 catheters by sub-galeal 
tubing (B). The trans-frontal and trans-cerebellar catheters target the tumour (blue) 
delivering drug along their distal trajectory (red) using a recessed-step catheter design 
(C). Intra-parenchymal infusion of sodium valproate was performed demonstrating 
hyperintensity on FLAIR sequences around each catheter (D). After two cycles of 
treatment, disease response was demonstrated by reduction in pontine volume and 
FLAIR hyperintensity (E). Post mortem histopathological analysis demonstrated positivity 





10 patients with DIPG underwent implantation of the drug delivery system, 9 of 
whom went onto receive pontine infusion of sodium valproate. Median overall 
survival for this cohort was longer than expected compared to the wider DIPG 
population. Surgical implantation was associated with one severe adverse event, but 
was otherwise well tolerated. Pontine infusions were associated with neurological 
deterioration, which in the most part was transitory; however, three patients 
sustained moderate to severe neurological deficits that failed to recover completely. 
How the mortality and morbidity of this treatment could be managed to improve 
survival and quality of life in patients is discussed.  
 
Figure 2.3. Survival curves for 10 children with diffuse intrinsic pontine glioma (DIPG) 
treated with sodium valproate administered by chronic intermittent convection 
































Multiple infusions were performed without life-threatening side-effects and most 
patients tolerated infusions and surgical implantation well. One response following 
treatment was identified demonstrating encouraging signs of efficacy. However, the 
extent to which we can attribute this, or the longer than expected survival in these 
patients, to CED is limited. Patient A received veliparib as part of a clinical trial 
(NCT01514201) and left the trial after being diagnosed with tumour progression. In 
retrospect, this may have represented pseudo-progression, which is clinically and 
radiologically indistinguishable from disease progression. Pseudo-progression 
represents an inflammatory response following tumour treatment and is associated 
with a more favourable prognosis (Carceller et al. 2016). Reduction in tumour 
volume after initiation of CED may have represented remission of this inflammatory 
process rather than response to treatment. Indeed, considering that patients had to 
be clinically fit to undergo surgery and selection of patients was subject to various 
clinical, anatomical and pathological considerations, there is a significant risk of 
selection bias. As such, the favourable response in one patient and the better than 
expected survival overall should be interpreted with caution and further treatment as 
part of a clinical trial should be prioritized. Most importantly, this preliminary 
experience demonstrates that chronic intermittent CED of sodium valproate can be 
feasibly performed in patients with DIPG. Moreover, it identifies the important 
challenges regarding safety of ongoing treatment.  
Most notably there was one death during treatment not attributable to progression of 
disease and thus must represent a central point for discussion in how the safety of 
pontine CED can be improved. Patient E’s ultimate deterioration occurred 3 weeks 
following initial implantation during an unrelated urological procedure under general 
anaesthetic performed whilst undergoing radiotherapy. It must be acknowledged that 
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children with brain tumours who have received radiotherapy have increased baseline 
risk of stroke, this is 100-fold but often as a delayed effect (Campen et al. 2012, 
Greene-Schloesser et al. 2012). Equally, patients with DIPG are at high risk of 
death- approximately 5% of patients with H3FA DIPG are dead by 4 months 
(Veldhuijzen van Zanten et al. 2017). However, the extent to which implantation 
could have contributed to this severe adverse event must be explored. Surgical 
intervention in these patients is known to be high risk. Historically, surgical resection 
has been avoided in DIPG due to excessive morbidity and lack of efficacy (Epstein 
and McCleary 1986). Stereotactic brain stem biopsy in a contemporary cohort of 130 
patients with DIPG is associated with a morbidity of 3.4% (Puget et al. 2015). 
Therefore, it can be expected that experimental surgery of this nature will be 
associated with significant risk. However, the tolerance of Patient E to surgery is 
dramatically contrasted with the good post-operative outcomes of other patients 
implanted using the same drug delivery system. As such, it is essential to reflect on 
how risk can be reduced in the future. 
Patient E’s surgery was remarkable for hypertension intra-operatively. It is 
understood that hypertension is a risk factor for intracerebral haemorrhage after 
cranial neurosurgery (Basali et al. 2000). It is possible therefore that intra-operative 
hypertension contributed to the eventual brain stem haemorrhage. Autonomic control 
is regulated by the central autonomic network, which consists of interconnected 
neural systems in the telencephalon, diencephalon and brainstem that co-ordinate 
sympathetic and parasympathetic output (Bennaroch 2012). The brain stem contains 
the nucleus of the solitary tract, the nucleus ambiguus and the dorsal motor nucleus 
of the vagus nerve, all of which form fundamental parts of the central autonomic 
network (Bennaroch 2012).  Experimental studies in animals demonstrate that 
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bilateral lesioning of the nucleus of the solitary tract produces acute hypertension, 
blood pressure lability, chronic hypertension and exaggerated hypertensive 
responses to environmental stress (Doba and Reis 1973, Nathan and Reis 1977). It 
is feasible therefore that physiological challenges arising from surgery and 
anaesthetic combined with instrumentation of brainstem in DIPG could increase the 
risk of autonomic dysregulation, hypertension and haemorrhage.  
Patient E was also distinct from the other patients by the absence of pre-implantation 
radiotherapy. It is possible that radiotherapy could act to reduce the risk of bleeding 
during drug delivery system implantation. Blood supply to the pons is provided by 
perforating arteries of the basilar artery and its branches. Endothelial cells are 
exquisitely sensitive to radiation ultimately resulting in reduction of the vascular 
network and ischaemia (Venkatasulu et al. 2018). Outside the brain, the acute 
effects of radiation can be used as a palliative procedure to control persistent 
tumoural bleeding (Kondoh et al., 2015). As such, it is possible that the contrasting 
surgical outcomes between Patient E and the rest of the cohort could be attributed to 
this effect of radiotherapy. Without further evidence conducted within a clinical trial, 
this is speculative. Nevertheless, at this early critical stage of developing CED for 
DIPG, further treatment of patients should be performed after radiotherapy. 
Lessons from Patient E demonstrate clear points about how to reduce surgical 
morbidity; however, the infusions were also associated with toxicity. Considering that 
patients receive multiple infusions during treatment, these represent important 
sources of morbidity for the child. All patients experienced some degree of 
neurological disability during infusion, which reportedly resolved within hours to days. 
Previously, neurological side-effects have been reported to occur after pontine 
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infusion as a delayed effect (Singleton et al. 2016) but this was not observed in this 
cohort. Significant side-effects were observed in Patient B, D and F who both 
developed disabling neurological side-effects during infusion that failed to recover to 
pre-infusion baseline. The cause of such side-effects could relate to the toxicity of 
the drug, the physiological effect of infusion or their interaction with the underlying 
tumour. Nevertheless, the impact of permanent neurological side-effects in DIPG, 
where quality of life is paramount, should be minimised. It is positive that such 
events only occurred in the minority of patients. However, the side-effects 
experienced by other patients at the time of infusion were indistinguishable from 
those that failed to recover in Patient D and F. As such, our ability to predict recovery 
from infusion-related deficits is limited and as a consequence the attending physician 
has to weigh the unknown risk of permanent deficit associated with continuing 
infusion versus the theoretical benefit of maximising infusion volume to increase the 
volume of treated disease. Balancing unknown risks versus unknown benefits is 
common when developing new treatment. However, particular to awake pontine 
infusion is that the calculation of risk versus benefit is made continually as side-
effects evolve in real time during drug administration. Managing such uncertainty 
with such frequency, therefore, presents many challenges for the child, the parent 
and the team treating the patient.  Improving our understanding of the clinical 
manifestations of pontine infusion therefore represent a priority for the development 
of pontine CED for DIPG.
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Table 2.1. Characteristics of 10 patients accepted for drug delivery system implantation for treatment with valproate monotherapy 
Patient Age at 
diagnosis 
(years) 






Additional CED therapies Additional treatment Survival from 
diagnosis (months) 
A 4 H3 K27M 6.1 5 (9) - 54 Gy Rtx, Veliparib 20 
B 7.7 - 10.1 1 (1) Panobinostat  
Newcastle disease virus, gallium maltholate, oral 
panobinostat, avastin 
23.6 
C 5.6 - 4.3 4(2) 
Separate Valproate 
Carboplatin 
Proton Beam therapy, oral metformin 14.9 
D 10.6 - 4.9 5 (10) 
Combined Valproate 
Carboplatin 
34 Gy RTx, immunotherapy, palliative radiotherapy 17.8 
E 7.3 H3 K27M 3.6 0 - 5.4 Gy Rtx (post-implant) 4.1 
F 11.2 - 5 2(3) - 54 Gy Rtx, Immunotherapy, intra-arterial therapy 23.5 
G 8 H3 K27M 3.5 2(3) Carboplatin 54 Gy Rtx, intra-arterial therapy 9.0 
H 9.3 H3 K27M 4.3 1 
Separate Valproate and 
Carboplatin 
54 Gy Rtx 6.4 
I 7.8 - 7.9 1 (1) 
Combined Valproate 
Carboplatin 
54 Gy Rtx , 4 cycles carboplatin 13.9 
J 6.9 - 3.3 4 (8) 
Combined Valproate 
Carboplatin 
54 Gy Rtx, palliative radiotherapy 13.5 
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Chapter 3 Development of a neurological scale to monitor 




Treating patients with diffuse intrinsic pontine glioma (DIPG) on compassionate 
ground using awake pontine infusion represents an important opportunity for the 
development as CED as a treatment for neurological disease. Repeated infusions of 
chemotherapy directly into the brainstem were feasible and many patients achieved 
favourable outcomes. On the other hand, this new treatment was accompanied by 
new patterns of treatment-related toxicity, which need to be better understood. 
Patients developed neurological deficits at the time of administration and their 
recovery was unpredictable. This neurological toxicity places additional burden on 
the patient, when quality of life is paramount. It complicates the design of treatment 
schedules requiring intensive monitoring in a paediatric intensive care unit (PICU), 
which increases costs and reduces availability. Furthermore, the attending physician 
has to balance risks and benefits in real-time weighing the risk of permanent deficit 
against the desire to control disease.  Quantifying and controlling neurological 
toxicity occurring during pontine CED would therefore represent a major advance in 
the development of the treatment.  
 
Complex decision making about risks and benefits is nothing new in translational 
medicine. Karnofsky et al, performed a study on patients with similarly inoperable, 
untreatable cancer in 1948 using a new chemotherapy, nitrogen mustard (Karnofsky 
et al. 1948). It was difficult to quantify the clinical benefit of treatment because 
despite there being ‘subjective and objective evidence of improvement’ many 
patients remained ‘bedridden’ (Karnofsky and Burchenal, 1949). Consequently, the 
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burden of the treatment remained difficult to justify and the types of patients most 
likely to benefit remained unknown.  This led to the concept of Karnofsky’s 
Performance Status (KPS), which measures functional impairment between 0-100 
with lower scores indicating worse function. This enables clinical decisions to be 
made regarding fitness for treatment, determine prognosis and compare patients 
between studies. Although Karnofsky’s Performance status represented an advance 
in how to translate new treatments, the way toxicity of new treatments were 
described was also problematic.   
 
Prior to 1982, toxicity during cancer treatment was described using ad hoc and 
inconsistent descriptions. The Acute Radiation Morbidity Scoring Criteria and 
Common Toxicity Criteria, which were later amalgamated into the Common Criteria 
for Adverse Events (CTCAE), provide detailed descriptions of side-effects arising 
from treatment (Trotti et al. 2000). However, pontine CED causes dynamic 
neurological changes that recover at varying points post-infusion and may even 
occur between infusions; this makes methods such as KPS and CTCAE less useful. 
Souweidane et al., 2018 addressed this problem in their Phase I trial by measuring 
toxicity at 7 days post infusion. However, such an approach cannot inform the risk-
benefit decisions made during infusion because deficits arise in real-time.  
Continuous neurological assessment during infusion is required to identify 
neurological deficits at onset and quantify recovery. It is possible to use conventional 
neurological examination as used in the patients treated with carboplatin and 
valproate monotherapy. However, infusions were still associated with significant 
toxicity, and inconsistent technique between assessors and assessments made 
identifying and communicating onset of deficit and recovery difficult. Patients treated 
 52 
with CED would therefore benefit from a reliable neurological assessment scale that 
could be performed before, during and after pontine infusion. This would enable the 
consistent documentation of neurological change during therapy and inform 
treatment decisions appropriately. I hypothesized that I could develop a reliable 
neurological assessment system that could use patient-reported symptoms and 
observed neurological signs to quantify brain stem dysfunction occurring during 




A literature search was conducted based on the cardinal signs and symptoms of 
DIPG: long tract signs, ataxia and cranial neuropathy (Figure 3.1). Only journal 
articles published within the last 10 years studying humans were included. Articles 
were excluded if they did not involve clinical assessment scales. Abstracts were 
reviewed to identify articles that used scales that elicited the cardinal features. 
Scales were selected if they had been validated in a paediatric population and could 
be conducted at the bedside without equipment. This left the pediatric National 
Institutes of Health Stroke Scale (pedNIHSS) (Ichord et al., 2011), the Scale for 
Assessment and Rating of Ataxia (SARA) (Schmidt-Hübsch et al., 2006), 
International Co-operative Ataxia Rating Scale (ICARS) (Trouliass et al., 1997) and 
the Brief Ataxia Rating Scale (Schmamahann et al., 2009). Scales were 
deconstructed into their individual items (Table 3.1). Items that did not assess long 
tract signs, cranial neuropathy or ataxia were excluded. Measures of visual function 
were also excluded due to the location of the optic pathway outside of the pons. 
Items that could not be completed safely while attached to the infusion set were 
excluded, i.e. measures of gait, stance and sitting balance.  
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Figure 3.1. Development of the Pontine Infusion Neurological Evaluation Score. A 
literature search was conducted to identify neurological scales that measure 
ataxia, long tract signs and cranial neuropathy as cardinal features of diffuse 
intrinsic pontine glioma. 4 scales were identified. A composite score of the 
pediatric National institutes of Health Stroke Scale and Scale for Assessment and 
Rating of Ataxia was generated. Modifications of the House-Brackmann Scale, a 
tongue range of motion scale and the Wong Baker Scale® were included in a 
Prototype Score, which was trialled in 20 infusions. The PINE Score was 
generated from the Prototype Score based on nursing feedback. 
PubMed Search: 
((scale stroke) OR scale ataxia) OR scale cranial nerve) AND ((childhood) OR (pediatric))  
Journal articles ≤10 years, human studies  
382 articles 
8 neurological scales 
pedNIHSS 
(Ichord et al., 2011) 
SARA 
(Schmidt-Hübsch et al., 
2006) 
House-Brackmann Scale 
(House and Brackmann, 
1985) 
Range of tongue motion  
(Lazarus et al., 2014) 







(Schmahmann et al., 2009) 
ICARS 
(Trouillas et al., 1997) 
3 scales not validated in 
children 
1 assessment required 
equipment 
374 did not include 
neurological scale(s) 
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The pedNIHSS provided validated items assessing consciousness, eye movement 
and limb power, which were included in the Prototype Score (Table 3.2). The 
assessment of facial movement was modified. Assessment of facial palsy using the 
pedNIHSS is weighted toward assessment of an upper motor neurone pattern of 
facial weakness, where the upper face is spared owing to bilateral input to the facial 
nuclei from the cerebral cortices (Figure 3.2). In pontine infusion, facial weakness 
could arise due to injury to descending corticobulbar fibres or outgoing facial nerve 
fibres and could also be bilateral.  
 
 
Figure 3.2. Anatomical basis of upper facial sparing in supra-nuclear facial 
weakness. (Image adapted from Busty A.J. and Kellogg D., 2015, Stroke vs Bell’s 
Palsy: Anatomy image, Evidenced Based Consult, available at: 
https://www.ebmconsult.com/articles/anatomy-stroke-vs-bells-palsy [Last accessed 
7/7/2019]) 
 
The House-Brackmann Scale (House and Brackmann et al., 1985) was reviewed as 
a well-established measure of facial nerve function, which uses gross inspection of 
the face, at rest and during movement. An advantage of the House-Brackman Scale 
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is that grading is positively correlated with disfigurement at rest and has been used 
to treat ophthalmic complications. However, the House-Brackmann Scale can be 
limited by poor agreement between trained observers, which is attributable to 
assessment of concurrent involuntary muscle contraction during voluntary movement, 
known as synkinesis (Coulson et al., 2005). The item for facial movement in the 
prototype Score was replaced with a simplified version of the House-Brackmann 
Scale (Table 3.2). 
 
The pedNIHSS also quantifies ataxia by assessment of limb movement. This is 
elicited using heel-shin slide and finger-to-nose testing. It is scored a maximum of 2 
points based on whether it is present in one or two or more limbs. This simplicity is 
advantageous when designing a scale to be used by non-experts. But, with only two 
points allocated, it does not award much weight to limb ataxia as a clinical sign. On 
the other hand, SARA, BARS and ICARS allocate 16, 8 and 52 points for limb ataxia 
respectively depending on its severity. Although more complex, the higher weighting 
for limb ataxia may better reflect its impact on functional outcome. On this basis, the 
simple examination technique and scoring principles of the pedNIHSS were kept but 
a point was allocated for each individual limb affected, which increases the weighting 
of ataxia in the overall score.  
 
SARA, ICARS and BARS also quantify ataxia by examining eye movements and 
dysarthria.  Items assessing ataxia using eye movements (i.e. nystagmus) were 
excluded due to the possible contribution of concomitant oculomotor, trochlear or 
abducens nerve palsies that could occur during pontine infusion. Dysarthria is 
common in pontine infusion, recorded in 15% of patients by Souweidane et al., 2019. 
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Further still, monitoring the ability to communicate is important when designing a 
score to monitor signs and symptoms of pontine infusion because of the risk of 
locked-in syndrome (Masuzawa et al., 1993). SARA, ICARS and BARS all score 
dysarthria by assessing normal conversation. Importantly, because the score is 
intended to monitor patients at regular intervals throughout infusions, assessing 
normal conversation could be limited by several factors such as distress of the 
patient, altered compliance during a long infusion or sleep. The adult NIHSS 
assesses dysarthria by assessing the repetition of mama, fifty-fifty, tip-top, baseball 
player, huckleberry and thanks (Brott et al., 1989). This technique was adopted using 
the SARA scoring criteria. 
 
The Prototype Score (Table 3.2) was completed after inclusion of additional items to 
assess steroid administration and analgesia - which could have ameliorated the 
clinical effects of pontine infusion- tongue movement and headache. A tongue 
movement item was repurposed from a scale used in oral cancer patients to assess 
range of tongue motion (Lazarus et al. 2014) because none of the scores included in 
the literature review assessed tongue movement directly. An item for headache 





The Prototype Score (Table 3.2) was trialled in 20 pontine infusions. All 
examinations were performed with the patient in bed semi-recumbent with the bed at 
45°. The Timed Up and Go (TUG) Test, as a validated timed walking test to measure 
mobility in children with neurological disease (Carey et al. 2016). Nurses who had 
received training in the use of the Prototype Score were given a paper survey (Table 
3.3). Based on nursing feedback, the Prototype Score refined into the Pontine 
Infusion Neurological Evaluation (PINE) Score (Table 3.4). The PINEScore was 
taught to PICU nurses during weekly seminars and were supported during infusions 
with bedside teaching.  
 
Reliability of the PINE Score 
Pontine infusions were supervised by a PINEScore-trained nurse. During each 
infusion, heart rate, blood pressure and respiratory rate were recorded independently 
by the attending nurse in conjunction with assessment of Glasgow Coma Scale, 
PINEScore and infusion parameters, including infusion volume and rate of infusion. 
Nurse-recorded scores were entered directly onto password-protected software, to 
which the attending doctor did not have access and recorded their assessment 
independently. Doctor-recorded scores were measured by observing the nurse’s 
assessment. Data acquired from the patient’s routine clinical care were used to 
measure reliability of the PINEscore and quantify neurological and physiological 
changes occurring during pontine infusion. Doctor-recorded PINEScores were paired 







Prototype neurological assessment scale 
The Prototype Score was and trialed in 5 patients D, E, F, J and H (see Chapter 2) 
during 20 infusions. Prototype Scores increased during infusion suggesting 
accumulating neurological signs and symptoms during pontine infusion. Mean 
Prototype Score was 5.4 and 6.7 at the beginning and end of infusion respectively, 
which reached statistical significance (p-value 0.01). Increase in Prototype Score 
was associated with impaired mobility measured using the TUG test. Mean TUG 
time at the beginning and end of infusion was 7.6 and 11.2 seconds respectively, 
which also differed with statistical significance (p-value>0.001). Change in prototype 
score and change in TUG Time were positively correlated with a Pearson Correlation 
Co-efficient of 0.267 (p-value >0.001). This suggested that the Prototype Score was 
a valid and sensitive tool for assessing neurological change during pontine infusion. 
 
Overall, 6/10 nurses agreed that conventional assessment including 
cardiorespiratory observation and Glasgow Coma Scale testing was helpful during 
pontine infusion. However, 9/10 either strongly agreed or agreed that the prototype 
assessment provided useful information during pontine infusion and 8/10 agreed or 
strongly agreed it could be easily performed with their existing workload. 6/10 nurses 
said assessment took 1-2 minutes and 9/10 of nurses felt confident or very confident 
using the assessment.  7/10 nurses reported that the assessment caused distress at 
the time of assessment; this was reported as occasionally mild distress by 3/7 
nurses. All nurses reported that assessment caused no distress or only mild 
occasional distress in parents. (Figure 3.4).  Particular comments included: 
“sometimes the children are distressed during infusion-there is no part in the score for this” 
“it is confusing about [sic] when we score for giving pain killers” 
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“sometimes the children are weak in an arm or leg but the score stays the same” 
“I had a patient complain of tingling in their face and arms, I don’t know how to score it” 
“not sure how to assess eye movements” 
“the children try hard to repeat the words, but sometimes they slur their speech when they aren’t 
concentrating” 
 
Based on experience and feedback from the Prototype Score, the Pontine Infusion 
Neurological Evaluation (PINE) Score was compiled as a composite score of 
brainstem dysfunction in patients receiving pontine infusion. Steroid and analgesia 
items were removed because prescription was based on clinical protocol rather than 
patient request.  Criteria for distress within the Consciousness item were included. 
Sensory items were included for the face and body. Examination definitions for eye 
movements were included stipulating that the limbus has to ‘buried’ in the medial or 
lateral epicanthus in the direction of gaze (Figure 3.3). Points for pupillary 
abnormalities were also included to detect eye signs in patients with total gaze 
paresis.  Extra points for limb drift, i.e. less than 10 cm, were added to reflect minor 
weakness.  
Figure 3.3. Burying the Limbus. Left lateral gaze is elicited 
demonstrating burying of the limbus in the lateral epicanthus of the left 
eye. Failure to bury the limbus in the direction of gaze in the right eye 
demonstrates weakness of the medial rectus. Image modified from Gold, 
D. Eye Movement Disorders: Conjugate Gaze Abnormalities. In: Liu, 
Volpe and Galetta’s Neuro-Ophthalmology. Third Ed. Diagnosis and 




























How much distress does performing the assessment cause for 







Very confident Confident Neither confident 
nor unconfident 
Unconfident Very unconfident 




























Strongly agree Agree Neither agree nor 
disagree 
Disagree Strongly Disagree 
Do you agree that conventional nursing assessment is appropriate 












Strongly agree Agree Neither agree nor 
disagree 
Disagree Strongly Disagree 
Do you agree that the prototype assessment provides useful 












Strongly agree Agree Neither agree nor 
disagree 
Disagree Strongly Disagree 
Do you agree the prototype assessment is easy to perform in 
combination with your existing workload?  
Figure 3.4. Nursing feedback regarding the Prototype Score developed to quantify neurological 
deterioration during pontine infusion of chemotherapeutics of children with diffuse intrinsic pontine glioma. 
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Preliminary validity testing of the PINE score 
Based on experience and feedback from the Prototype Score, the PINE Score was 
compiled as a composite score of brainstem dysfunction in patients receiving pontine 
infusion. Overall 30 pontine infusions in a total of 9 children receiving chemotherapy 
by pontine CED were analysed. The median age of children treated was 6.6 years 
(IQR 5.9-6.9). A median of 3.5 (IQR 3-4) infusions were analysed for each patient. 
Infusions analysed were at different times relative to time of diagnosis (median 6.9 
months; IQR 5.9-8.8) and stage of CED treatment (median 2nd cycle of CED; IQR 
1.5-3. Each infusion took an average of 7.9 hours (range 5-10 hours) to complete. 
 
Inter-rater reliability testing was performed using paired examinations recorded by 
the attending doctor and nurse at hours zero and hours six of infusion. Overall, there 
was strong association between nurse and doctor scores over both time points with 
a Spearman correlation coefficient of 0.985 (P<0.001). Mean PINE score was 5.49 
and 5.5 recorded by nurses and doctor respectively (p-value =0.727). Self-reported 
items (headache, facial and body sensation) demonstrated 100% agreement. There 
was absolute agreement between doctors and nurses in 45/60 cases and was within 
one point in 57/60 cases. The intra-class correlation coefficient (ICC) was 0.98 (95% 
CI 0.97-0.99; p-value<0.001) with a Chonbach’s alpha value of 0.98 and a Kendall’s 
concordance co-efficient of 0.99. Bias in scoring estimated using Bland and Altman 
methods was very small at 0.03 (Figure 3.5) and disagreement did not demonstrate 
proportional bias. Also, there was excellent agreement over both time points using 
weighted kappa calculations. Weighted kappa values were not calculated for scoring 
of consciousness because all patients were keenly alert at the time of paired 
assessment. The PINE score was also reliable when both time points were 
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examined separately. At hour zero, mean PINE Score was 3.9 and 3.8 when 
recorded by nurses and doctor respectively (p-value=0.184). At hour six, mean PINE 
score was 7.0 and 7.2 recorded by nurses and doctor respectively (p-value =0.345). 
ICC at hour zero was 0.99 (95% CI 0.98-0.99; p-value<0.001) with a Chonbach’s 
alpha value of 0.99 and a Kendall’s concordance co-efficient of 0.99. ICC at hour six 
was 0.98 (95% CI 0.93-0.99; p-value<0.001) with a Chonbach’s alpha value of 0.98 
and a Kendall’s concordance co-efficient of 0.97. Weighted kappa values also 




Figure 3.5. Agreement and reliability of the PINEScore. Kappa plots of agreement on 
PINEScore recorded by nurse and doctor at hour zero and hour six of infusion (A). A 




The PINE Score was developed from validated measures of neurological function. It 
was first trialled as a Prototype Score on patients receiving pontine infusion as an 
adjunct to conventional monitoring. The prototype score increased after infusion 



































































































































































Mean PINEScore of nurse and doctor 
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increasing TUG time suggesting worsening mobility after infusion.  Nurses agreed 
that the prototype was useful; most reported that it took 1-2 minutes and that it was 
manageable with their existing workload. Based on their feedback, the prototype was 
finalised into the PINEScore. Using data from 30 infusions at two time points, the 
PINEScore had excellent inter-rater reliability and there was excellent agreement 
between items.  
 
Developing and validating a new clinical assessment scale alongside treatment on 
compassionate grounds is limited in several ways. Awake pontine infusion in DIPG is 
a treatment limited to a very small number of patients administered by an even 
smaller group of healthcare professionals. This limits the ability to acquire peer-
validity as many experts in paediatric neurology would not have any experience of 
the treatment. It is likely that if this treatment is taken up in the future the PINEScore 
may be refined as the wealth of knowledge about awake pontine infusion grows. 
Moreover, inter-rater reliability was assessed without an experimental protocol using 
data acquired during routine assessment of the patients. Indeed, the PINEScores 
were scored simultaneously at the child’s bedside as part of their clinical care and it 
cannot be excluded that unintentional non-verbal communication took place. 
Examiners were also not blinded to the stage of the infusion therefore it is possible 
that perceptions about higher risk of neurological disability as infusion progresses 
may have influenced score interpretation. The PINEScore was only measured in a 
very small number of children, which is ultimately due to the small numbers of 
children receiving the treatment. It could be argued that each infusion represents a 
different neurological phenotype and so the estimates of reliability may be more 
robust than the small number of children studied would suggest. Nevertheless, the 
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robustness of reliability estimates would certainly be improved by being tested in 
patients with and without DIPG in children of different ages. Indeed, a further 
consideration is how to administer the PINEScore in different languages. DIPG is a 
rare disease and only a subpopulation are eligible for CED, therefore, patients from 
different countries are likely to be treated in the same unit. The use of a score to 
monitor safety of infusion must therefore be validated in a range of languages to 
ensure safety. 
 
An important issue raised by the nursing staff was the distress caused by the 
examination. The frequency and severity of procedural anxiety in awake pontine 
infusion is unknown. Anecdotally, many patients tolerate infusion very well while 
others demonstrate high degrees of anxiety. Children treated with awake pontine 
infusion have to face many challenges. The families and children have undergone 
major life changes in a short space of time; often patients fly long haul flights to 
receive treatment with the added uncertainty of receiving experimental therapy. All of 
these could compound their ability to cope. The experience from the child’s 
perspective is difficult to decipher. Reassuringly, it is understood that in clinical 
situations parents under estimate the health-related quality of life of their children 
(Upton, 2008). Nevertheless, the reported distress during examination requires 
further investigation. Ensuring safety of infusion is paramount, and if indeed, 
systematic examination does adds to the procedural anxiety, it needs to be 
understood how it can be reduced and whether the benefits are justified. Bearing in 
mind that no infusion was associated with critical adverse events while using the 
PINEScore, it may be possible that infusions can be conducted outside of PICU; this 
could help allay anxiety. 
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In conclusion, we describe a novel scoring system to that systematically measures 
neurological signs and symptoms during pontine infusion. Preliminary analysis from 
data acquired from treatment on compassionate grounds suggests it can be feasibly 
delivered hourly during infusion. It is reliable and correlates with other measures of 
neurological function. It is intended that this scoring system will improve the safety of 
awake pontine infusion and help understand how harm can be avoided in the future. 
In the absence of a better validated alternative, the PINEScore has become part of 




Table 3.1. Individual items from four neurological assessment scales validated in 
children: the pediatric National Institutes of Health Stroke Scale (pedNIHSS), Scale 
for Assessment and Rating of Ataxia (SARA), Brief Ataxia Rating Scale (BARS) and 
International Co-operative Ataxia Rating Scale (ICARS)  
 








Item Level of 
consciousness (6) 
Best Gaze (2) 
Visual (3) 
Facial Palsy (3) 
Motor Arm and leg 
power (20) 
Limb ataxia (2) 
Sensory (2) 





































Ask: “Do you have a 
headache? How much does it 
hurt?” 
Examiner points to Wong-
Baker faces 
 No headache (0) 
 Hurts a little (1) 
 Hurts little more (2) 
 Hurts even more (3) 
 Hurts a whole lot (4) 
 Worst hurt (5) 
Analgesia requirements  No analgesia given (0) 
 Analgesia given (1) 
Steroids requirements 
 
 No steroids given (0) 
 Steroids given (1) 
Consciousness  
Look at the patient, which 
description is most 
appropriate? 
 Keenly alert (0) 
 Rousable but alert with light stimulation (1) 
 Rousable with strong stimulation (2) 
 Reflex movements or unresponsive (3) 
Eye movements 
Ask the patient “Look up and 
down, left and right” 
[Ignore nstagmus] 
 Full range of eye movements (0) 
 Abnormal/limited movements in one eye (1) 
 Abnormal/limited movements in both eyes (2) 
 No movement in either eye (3) 
Facial movements  
Note the face at rest and on 
movement “Raise your 
eyebrows, scrunch up your 
eyes, blow out your cheeks, 
show me your teeth” 
 Normal (0) 
 Mild asymmetry apparent on movement only (1) 
 Unilateral partial paralysis of upper face evident at rest (2) 
 Total paralysis of upper and lower face on one side or partial 
paralysis of both side of the face evident at rest (3) 
 No facial movements (4) 
Tongue movements  
Ask the patient “Stick your 
tongue out as far as you can”  
 Normal range of movement (0) 
 Deviation with normal protrusion (1) 
 Unable to protrude tongue beyond lower lip margin (1) 
Arm Power 
The limb is placed in the 
appropriate position: extend 
the arms (palms up) at 90˚. 
Score each arm separately. 
 No drift; limb holds 90˚ for full 10 seconds (0) 
 Drift; limb holds 90˚, but drifts down before full 10 seconds; does 
not hit bed or other support (1) 
 Some effort against gravity; limb cannot get to or maintain (if cued) 
90˚, drifts down to bed, but has some effort against gravity (2) 
 No effort against gravity; limb falls (3) 







Table 3.2 continued. Prototype Score for assessment of neurological deterioration 
during pontine infusion 
Limb ataxia 
The finger-nose-finger test 
and heel shin test 
 Normal co-ordination (0) 
 Present in one limb (1) 
 Present in two limbs (2) 
 Present in three limbs (3) 
 Present in four limbs (4) 
Leg power 
The limb is placed in the 
appropriate position: leg 
raised with leg straight and 
heel 30 cm off the bed.  
Maintain for 5 seconds. Score 
each leg separately. 
 No drift; limb held in position for full 5 seconds (0) 
 Drift; limb held in position but drifts; does not hit bed or other 
support (1) 
 Some effort against gravity; limb cannot get to or maintain 30 cm 
above bed drifts down to bed, but has some effort against gravity 
(2) 
 No effort against gravity; limb falls (3) 
 No movement (4) 
Speech 
Ask the patient to repeat 
‘huckleberry, mama, fifty-fifty, 
thanks, baseball, caterpillar’ 
 Normal  
 Suggestion of speech disturbance (1) 
 Impaired speech, but easy to understand (2) 
 Occasional words difficult to understand (3) 
 Many words difficult to understand (4) 
 Only single words understandable (5) 
 Speech unintelligible / anarthria (6) 
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Table 3.3. Prototype Score: Nursing Feedback 
 
1. To what extent do you agree conventional nursing assessment is appropriate to safely 
monitor patents receiving brainstem CED? Please tick the appropriate box 
Strongly agree Agree 
Neither agree not 
disagree 
Disagree Strongly disagree 
2. To what extent do you agree the Prototype Score provides useful information whilst 
monitoring patients receiving brainstem CED? Please tick the most appropriate box 
Strongly agree Agree 
Neither agree not 
disagree 
Disagree Strongly disagree 
3. To what extent do you agree that the Prototype Score is easy to perform in combination with 
your existing workload? Please tick the most appropriate box 
Strongly agree Agree 
Neither agree not 
disagree 
Disagree Strongly disagree 
4. How long does the Prototype Score take to perform? Please tick the most appropriate box 
< 1minute 1-2 minutes 3-5 minutes 5-10 minutes >10 minutes 
5. How much distress does performing the assessment cause for most patients in your 










6. How much distress does performing the assessment cause for most parents in your 










7. How confident are you using the assessment in pontine infusion? Please tick the most 
appropriate box 
Very confident Confident 
Neither confident 
nor unconfident 
Unconfident Very confident 








































Ask: “Do you have a 
headache? How much does it 
hurt?” 
Examiner points to Wong-
Baker faces 
 No Headache (0) 
 Hurts a little (1) 
 Hurts little more (2) 
 Hurts even more (3) 
 Hurts a whole lot (4) 
 Worst hurt (5) 
Consciousness  
Look at the patient, which 
description is most 
appropriate? 
 Keenly Alert (0) 
 Distress (1) 
 Rousable but alert with light stimulation (2) 
 Rousable with strong stimulation (3) 
 Reflex movements or unresponsive (4) 
Eye movements 
Ask the patient “Look left and 
right” 
[Ignore nystagmus] 
 Buries the limbus in the epicanthi of the direction of gaze on both 
sides (0) 
 Restricted gaze in one eye (1) 
 Restricted gaze in both eyes (2) 
 Total gaze paresis with normal pupils (3) 
 Total gaze paresis  with abnormal pupils(4) 
Facial Sensation 
Ask the patient 
“Do you have 
numbness or tingling? If so, is 
it painful? If so, is it severe?”. 
 No numbness or tingling or pain in the face (0) 
 Non painful sensory change (1) 
 Moderately painful sensory change (2) 
 Severely painful sensory change (3) 
Facial movements  
Note the face at rest and on 
movement “Raise your 
eyebrows, scrunch up your 
eyes, blow out your cheeks, 
show me your teeth” 
 Symmetrical face at rest and throughout all movements (0) 
 Symmetrical at rest with obvious asymmetry during movement 
involving the lower face only (1) 
 Symmetrical at rest with obvious asymmetry during movement 
involving the upper face (2) 
 Asymmetrical at rest with obvious asymmetry during movement 
lower face only (3) 
 Asymmetrical at rest with obvious asymmetry during movement 
involving the upper face (4) 
 Barely perceptible or no movement on one side of the face (5) 
 No movement on either side of the face (6) 
Tongue movements  
Ask the patient “Stick you 
tongue out as far as you can”  
 Normal range of movement (0) 
 Deviation with normal protrusion (1) 
 Unable to protrude tongue beyond lip margin (1) 
Body Sensation 
Ask: “Do you have numbness 
of tingling (in the arms legs or 
body)? If so, is it painful? If 
so, is it severe?” 
 No numbness or tingling or pain in the body or limbs (0) 
 Non-painful sensory change (1) 
 Moderately painful sensory change (2)  
 Severely painful sensory change (3) 
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Table 3.4 continued. Pontine Infusion Neurological Evaluation Scale 
  
Arm Power                          
The limb is placed in the 
appropriate position: extend 
the arms (palms up) 90˚. Drift 
is scored if the arm falls 
before 10 seconds. Score 
each arm separately. 
 No drift; limb holds 90˚ for full 10 seconds. (0) 
 Minor Drift; limb holds 90˚, but drifts down <10 cm or pronates 
before full 10 seconds; does not hit bed or other support (1) 
 Drift; limb holds 90˚, but drifts down >10 cm before full 10 seconds; 
does not hit bed or other support (3) 
 Some effort against gravity; limb cannot get to or maintain (if cued) 
90˚, drifts down to bed, but has some effort against gravity. (3) 
 No effort against gravity; limb falls. (4) 
 No movement. (5) 
Leg power                          
The limb is placed in the 
appropriate position: leg 
straight with heel raised 30 
cm above the bed. Maintain 
for 5 seconds. Score each leg 
separately. 
 No drift; limb held with heel 30 cm off bed for 5 seconds (0) 
 Drift; limb held above bed but drift less than 10 cm or external 
rotation at hip (1) 
 Drift; limb held with heel above bed but drift more than 10 cm; does 
not hit bed or other support (2) 
 Some effort against gravity; limb cannot get to or maintain heel at 
30 cm above bed; drifts down to bed, but has some effort against 
gravity (3) 
 No effort against gravity; limb falls. (4) 
 No movement (5) 
Limb ataxia 
The finger-nose-finger test 
and heel shin test 
 Normal co-ordination (0) 
 Present in one limb (1) 
 Present in two limbs (2) 
 Present in three limbs (3) 
 Present in four limbs (4) 
Speech 
Ask the patient to repeat 
‘huckleberry, mama, fifty-fifty, 
thanks, baseball, caterpillar’ 
 Normal pronunciation and normal conversational speech (0) 
 Suggestion of speech disturbance in conversational speech only (1) 
 Suggestion of speech disturbance during pronunciation (2) 
 Slurring of words (3) 
 The words are easily understood but there is obvious slurring (4) 
 Difficult to understand (5) 
 Noises only (6) 




Chapter 4. Chronic intermittent convection enhanced delivery of 
carboplatin and sodium valproate to the brain stem in children 




The Functional Neurosurgery Research Group has amassed considerable 
experience of awake pontine infusion following treatment of several patients with 
DIPG on compassionate grounds using carboplatin and sodium valproate as 
monotherapies. Carboplatin, as an established anti-neoplastic agent, was used in 5 
children with some favourable results. However, carboplatin infusion was associated 
with side-effects (Singleton et al., 2016) and further patients went onto receive 
sodium valproate in a hope to reduce the burden of neurological disability from 
pharmacological toxicity. 10 patients were then recruited for sodium valproate 
administered by CED. However, switching to sodium valproate monotherapy was still 
associated with side-effects during infusion and failed to control disease in 4 patients.  
Preclinical studies show sodium valproate and carboplatin kill DIPG cells 
synergistically in vitro without added toxicity (Killick-Cole et al. 2017). It was 
hypothesized that the combination of carboplatin and sodium valproate would 
demonstrate increased efficacy compared to sodium valproate alone and enable 
reduction in the concentration of sodium valproate. Using a two-day infusion regime, 
patients were treated as part of a convenience pilot cohort on compassionate 
grounds. Children with DIPG were infused with combined sodium valproate, the 







Ethics and consent 
As described in Chapter 2, implantation was approved by the Medicines and Health 
products Regulatory Authority. Treatment of patients using CED was approved by an 
institutional ethics committee at Harley Street Clinic Children’s Hospital. Parents 
were consented for the experimental nature of the treatment and the use of their 
child’s information for treatment development and for scientific publication. 
 
Patient selection 
Patients D, I and J were initially accepted for treatment with sodium valproate 
monotherapy and were already implanted with the chronic implantable drug delivery 
system. 5 patients were accepted for implantation and infusion with combined 
sodium valproate and carboplatin therapy. Eligibility for treatment and method of 
drug delivery system implantation has been previously described in Chapter 2. 
 
Pontine Infusions 
Carboplatin (0.18 mg/mL) and sodium valproate (14.4 mg/mL) were suspended in 5 
mL aCSF in sterile conditions and were supplied in four pre-filled syringes for 
infusion and connected to the drug delivery system using the transcutaneous bone 
anchored port (TBAP), as described in Chapter 2. Cycles were performed at 4-6 
week intervals. All patients who were implanted for infusion of combined carboplatin 
and sodium valproate received infusion within 72 hours of drug delivery system 
implantation. Patients were monitored during infusion by continuous 
cardiorespiratory monitoring and regular neurological evaluation using the Pontine 
Infusion Neurological Evaluation (PINE) Score, which was developed specifically for 
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this purpose (see Chapter 3). The ramping regime used to initiate infusion is 
described in Chapter 2. Infusion regime was changed from a 4 catheter 
simultaneous infusion to an infusion performed through transfrontal catheters and 
transcerebellar catheters on separate days of each cycle. Due to the reduced 
accumulative flow rate arising from switching to a two-catheter regime, the maximum 
rate of infusion per catheter was increased upto 0.4 mL/hr if tolerated. Again, 
infusion was continued to achieve maximum volume of infusion and was limited by 
onset of significant neurological signs or symptoms. This new infusion regime 
enabled neurological deficits to be lateralised to specific catheters, e.g. a right 
cerebellar catheter in the right corticospinal tract would elicit left sided hemiparesis. 
This was determined using a schema (Figure 4.1). If a deficit could be localised to a 
specific catheter the flow rate would be reduced by 50%, if the deficit did not resolve 
the infusion would be stopped. Side-effects that occurred during infusion defined 
according to Common Terminology Criteria for Adverse Events (CTCAE) (Version 
5.0) and whether they persisted for longer than 24 hours or 4 weeks. Recovery of 
deficit was determined by a combination of clinical examination, review of outpatient 
notes and parent interview.  3D tumour volume was calculated by outlining tumour 
boundary on pre-implantation axial T2-weighted slices on neuro│inspire™. Magnetic 
resonance imaging (MRI) was performed before and after the first infusion of each 
cycle if tolerated by the patient. Increased hyperintensity on T2* and fluid attenuated 
inversion recovery (FLAIR) sequences was used as a proxy of CED (Sampson et al. 
2007, Tisnado et al. 2016).  
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Figure 4.1. Schematic diagram of axial pons with transfrontal and transcerebellar 
catheters in situ. Side-effects arising from trans-cerebellar catheters (A) and (C) are 
likely to result in contralateral weakness of the face (with sparing of the upper face), 
arm or leg, sensory disturbance affecting the face or body or ipsilateral facial 
weakness (involving upper and lower face) and cerebellar dysfunction. Infusion 
through the catheters in the dorsal pons (D) could cause headache, 
ophthalmoplegia, tongue weakness, facial weakness (involving upper and lower 
face). Infusion through the ventral pons (B) could cause change in sensation in the 
arms or leg, irritability or quadriparesis. Catheters shown in blue. Expected volume of 




8 patients with a median age of 6.6 years at diagnosis (range 3.6-10.7 years) were 
infused with combined carboplatin and sodium valproate (Table 4.1). Patients K, L 
and M had biopsy-confirmed World Health Organisation Grade IV tumour with H3 
K27M mutations (Louis et al. 2016). The remaining patients had radiological and 
clinical findings consistent with DIPG. Patients were implanted at a median of 4.6 












cm3 (range 7.7-20.2 cm3). Surgery was well tolerated by all patients. CED infusion 
commenced within 72 hours of implantation in all 8 cases.  
 
Figure 4.2. Treatment of the diffuse intrinsic pontine glioma using a chronic, 
implantable drug delivery device. 3D reconstructed computer tomography of a four-
catheter drug delivery system is shown in situ (a). Recessed stepped catheters 
provide controlled reflux (red) along the distal catheter trajectory targeting the tumour 
(blue) (b). Fluid-attenuated inversion recovery sequences of the left cerebellar and 
frontal catheters before (c, e) and after (d, f) infusion of 4.1 mL of chemotherapy 




36 cycles of combined carboplatin and sodium valproate were administered in total 
consisting of 55 separate infusions with a median of 3 cycles per patient (range 1-6; 
Table 4.2) at a median interval of 33 days between cycles (range 23-66 days).  35/36 
cycles consisted of two infusions on consecutive days. The second infusion of 
Patient I’s first cycle of combined therapy was contra-indicated by residual facial 
weakness from the previous day’s infusion. Patient I went onto develop progressive 
disease before her next cycle and received no further CED. Mean infusion time was 
7.6 hrs (range 5-11 hrs). High pressures occurred during infusion due to flow 
impedance within the external system, which was corrected by re-application of the 
application set where necessary. Post-infusion MRI, when performed, demonstrated 
increasing pontine volume and increased hyper-intensity consistent with CED in all 
cases (Figure 4.2). All patients were discharged within 24 hours of finishing infusion. 
Overall a mean volume of 4.4 mL (range 3.0 mL-5.6 mL) was achieved in each 
infusion.  
 
Patient D, I and J had previously received other therapy by CED before switching 
onto combined therapy (Table 4.3). Patient D received 4 cycles (6 infusions) of 
sodium valproate monotherapy, while Patient I and J had received a cycle of sodium 
valproate and carboplatin as monotherapy respectively before commencing 
combined treatment. 
 
Side-effects occurred during every CED infusion; however, no patient suffered 
severe or life-threatening complications. 62% (34/55) of infusions were associated 
with headache. Headache was mild to moderate in all but one infusion, which was 
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relieved by regular analgesia. Headache resolved after stopping the infusion in all 
cases. Abducens nerve disorders, facial muscle weakness, dysarthria, ataxia, right 
or left sided weakness were identified in 29% (16/55), 31% (17/55), 29% (16/55), 38% 
(21/55) and 60% (33/55) infusions respectively. In all cases severity of symptoms 
were mild - moderate and in most cases these deficits returned to pre-infusion 
baseline within 24 hours of stopping infusion. However, all patients developed 
neurological symptoms during CED treatment that persisted for over 24 hours and 6 
patients acquired at least one deficit that failed to recover after 4 weeks of follow-up 
(Table 4.2). Owing to the observed neurological toxicity, the carboplatin 
concentration was reduced to 0.12 mg/mL due to suspected pharmacological toxicity; 
this was performed in 6 cycles (Table 2). However, side-effect profiles between 
cycles using different concentrations of carboplatin were comparable. Similarly, 
Patients D, I and J who had previously received CED of sodium valproate and/or 
carboplatin as monotherapies, also experienced similar side-effects during infusion 
similar to combined therapy. Despite the observed toxicity, patients maintained 
baseline performance status up to the diagnosis of progression and there were no 
reports of systemic toxicity associated with combined treatment.  
 
No port failed or became unstable requiring replacement. All patients reported 
serous exudate around the port. Three patients had confirmed infection around the 
port but no specific pathogen was isolated. All cases were successfully treated with 
oral antibiotics. There was no evidence of intra-cranial infection, haemorrhage or 
cerebrospinal fluid leak arising during or after implantation. Patient L and N were 
found to have increased hyperintensity within the pons on T2 weighted-imaging after 
the 3rd and 2nd cycle respectively. This was associated with minimal change in their 
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clinical phenotype and the radiological changes subsequently improved in Patient L 
(Figure 4.3) and stabilised in Patient N. This was suggestive an underlying 
inflammatory process such as pseudo-progression (Carceller et al. 2016).  
 
Median overall survival was 13.9 months (range 8.6-27.0 months) with one patient 
still alive at time of submission. Tumour in Patient D remained stable after treatment 
with sodium valproate monotherapy but after treatment with combined therapy there 
was evidence of reduced tumour signal and volume (Figure 4.3). Patient D and L 
demonstrated lepto-spinal metastasis and went onto receive palliative radiotherapy. 
Patient J developed thalamic disease outside of the volume of distribution 
suggesting local control of disease (Figure 4.3) and went onto receive palliative 
radiotherapy.  Patient M developed extensive cervicothoracic lepto-spinal metastasis, 
was palliated and died 8.6 months after diagnosis. Patient I and K progressed within 
the pons dying 13.9 and 8.9 months from diagnosis after receiving 1 infusion (1 cycle) 
and 4 infusions (2 cycles) of combined therapy by CED.  
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Figure 4.3. Radiological changes in patients receiving pontine infusion of carboplatin 
and sodium valproate by chronic intermittent convection enhanced delivery (CED) for 
the treatment of diffuse intrinsic pontine glioma (DIPG). Fluid attenuated inversion 
recovery (FLAIR) sequences along the left frontal trajectory are shown for Patient B 
at implantation (a) and after infusion demonstrating drug distribution within the pons 
(b). After treatment with 4 cycles of sodium valproate monotherapy the tumour was 
unchanged (d) at 14 months following diagnosis after 5 cycles of combined therapy 
volume and signal within the pons had reduced (d). FLAIR sequences are shown 
along the trajectory of the left cerebellar catheter at implantation in Patient L (e), after 
the third cycle of CED, demonstrating increased intensity within the treatment 
volume (f) resolving 12 weeks later (g). FLAIR sequences for Patient J along the 
right frontal trajectory are shown at implantation (h) after infusion demonstrating 






8 children with DIPG received awake pontine infusion of sodium valproate and 
carboplatin as combined CED treatment on compassionate grounds. There were 
encouraging signs of efficacy. Overall patients survived longer than expected for 
patients with DIPG. There were two objective responses. Progression of disease 
also occurred outside of the pons in three cases, suggesting that pontine infusion 
may locally control disease. Implantation of this chronic, implantable drug delivery 
system was also well tolerated allowing repeated infusions. This experience has 
identified key challenges in developing awake pontine infusion as a feasible 
treatment that should be interrogated as part of a clinical trial. 
 
Figure 4.4. Survival curves for 8 children with diffuse intrinsic pontine glioma (DIPG) 
treated with combined valproate-carboplatin administered by chronic intermittent 
convection enhanced delivery versus the SIOPE DIPG Registry (Veldhuijzen van 

































There are several important lessons from this experience. It is important to exclude 
patients who cannot be feasibly treated. Experience from this cohort, demonstrated 
that infusion volume and the neurological side-effects of CED are important factors 
for developing eligibility criteria. Using this catheter configuration, disease beyond 
the pons, the immediately adjacent midbrain and cerebellar peduncles cannot be 
reached at an infusion volume of 4-5 mL.  Similarly, tumour >36 cm3 would not be 
covered by a volume of infusion of 9-10mL over 2 days’ of infusion. Hence, patients 
with disease outside the pons and/or >36 cm3 would be unlikely to be treated 
successfully. Indeed, considering the side-effects that can arise from pontine infusion, 
the patient’s pre-morbid status should also be carefully evaluated. Patients with poor 
performance status or severe neurological impairments at baseline may not tolerate 
CED. As such, eligibility criteria for a future trial should include limits on disease 
volume, anatomical distribution and clinical status of the patient.  
 
Importantly, pontine disease remained stable in 6 patients who received repeated 
infusions of carboplatin and sodium valproate. Expansion of radiological disease 
within the pons predicts poor outcome and progression of DIPG is associated with 
severe neurological symptoms (Steffen-Smith et al. 2014, Veldhuijzen van Zanten et 
al. 2016). If CED can control pontine disease locally it could improve quality of life 
and extend survival. Indeed, two patients had features consistent with pseudo-
progression, which is associated with better prognosis (Carceller et al. 2016). The 
causes of this are unclear and can occur following radiotherapy (Carceller et al. 
2016). However, it is possible that local delivery of chemotherapeutics, particularly 
histone deacetylase inhibitors, may initiate local immune activation.  
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It is important to weigh potential advantages of local delivery against the expected 
toxicity of the treatment. Like infusion with carboplatin and sodium valproate as 
single agents, combined therapy was associated with neurological deficits that were 
comparable in type and severity to those reported in the trial published by 
Souweidane, et al., 2018. Reported side effects occurred exclusively during infusion, 
the cause of which in unclear. Studying these side effects using the PINEScore 
could elucidate the cause and predictors of such toxicity. 
 
In conclusion, this experience of treating DIPG using combined carboplatin and 
sodium valproate delivered directly to the pons using a chronic, implantable drug 
delivery system was feasible, was not associated with treatment-related life-
threatening events and demonstrated encouraging signs of efficacy. Weighing the 
potential benefits of local control of disease versus the impact of pontine infusion on 
quality of life in DIPG requires study in an appropriately designed clinical trial using 
validated outcome measures designed to evaluate CED and DIPG. 
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Table 4.1. Characteristics of 8 patients receiving chronic, intermittent convection enhanced delivery of combined carboplatin and 
sodium valproate for the treatment of diffuse intrinsic pontine glioma 
Patient Age at 
diagnosis 
(years) 












Additional treatment Survival from diagnosis 
(months) 
D 10.6 - 4.9 17.8 5 (10)** 





I 7.8 - 7.9 16.9 1 (1)** 4 cycles carboplatin 13.9 








L 10.7 H3K27M 4.2 16.2 6 (12) 
Post CED- Palliative 
radiotherapy 
20.6 
M 6 H3K27M 4.9 15.8 3 (6) - 8.6 
N 3.6 - 3.6 11.7 3 (6) - 15.2 
O 5.7 - 6.5 7.7 4 (8) 
3 cycles carboplatin and 








Table 4.2. Neurological toxicity occurring during pontine infusion according to Common Terminology Criteria for Adverse Events 
Version 5.0 in 8 patients with diffuse intrinsic pontine glioma treated with chronic, intermittent convection enhanced delivery of 
carboplatin and sodium valproate 
Patient Full recovery within 4 weeks 
(Grade) 
Persistent at 4 weeks 
(Grade) 
D Right-Sided Weakness (1); 
Facial muscle weakness (1); Left-Sided Weakness (2);  
Abducens nerve disorder (1) 
I 
Facial muscle weakness (1); Left-sided weakness (1); Ataxia (1); 
Dysarthria (1) 
- 




Abducens nerve disorder (1); Facial muscle weakness (2); 
Left-sided weakness (2) 
L Abducens nerve disorder (1) Left-sided weakness (1) 
M Ataxia (1) - 
N 
Abducens nerve disorder (1); Ataxia (1); Dysarthria (1); Right-sided 
weakness (1) 
Facial muscle weakness (2); Left-sided weakness (1) 




Table 4.3. Treatment schedule of 8 patients with diffuse intrinsic pontine glioma treated with combined sodium valproate (VA) and 
carboplatin (C) administered by chronic intermittent convection enhanced delivery  










Drug VA  VA  VA VA C+VA C+VA C+VA C+VA C+VA 
Infusion 
day 
1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
Volume 
(mL) 




1 67 99 
Pontine progression at 
5.2 months after CED 
 
- - - - - 
Drug VA C C+VA 
Infusion 
day 
1 2 1 2 1 2 
Volume 
(mL) 




1 31 58 85 130 163 
Thalamic progression at 
6.6 months after CED 
 
- - 
Drug VA C 0.18 C+VA C+VA C+VA C+VA 
Infusion 
day 
1 2 1 2 1 2 1 2 1 2 1 2 
Volume 
(mL) 





Pontine progression at 
2.7 months after CED 
 
- - - - - - 
Drug C+VA C+VA 
Infusion 
day 
1 2 1 2 
Volume 
(mL) 






Table 4.3 continued. Treatment schedule of 8 patients with diffuse intrinsic pontine glioma treated with combined valproic acid and 
carboplatin administered by chronic intermittent convection enhanced delivery  




1 29 60 114 156 200     
Drug C+VA C+VA C+VA C+VA *C+VA *C+VA     
Infusion 
day 
1 2 1 2 1 2 1 2 1 2 1 2 










3 41 73 
Lepto-spinal metastasis 
at 2.7 months after CED 
 
- - - - - 
Drug C+VA C+VA C+VA 
Infusion 
day 
1 2 1 2 1 2 
Volume 
(mL) 




2 53 108 
Died 15.2 months 
following diagnosis 
 
- - - - - 
Drug C+VA *C+VA *C+VA 
Infusion 
day 
1 2 1 2 1 2 
Volume 
(mL) 




2 29 64 100 
Alive 23.0 months from 
diagnosis 
 
- - - - 
Drug C+VA C+VA *C+VA *C+VA 
Infusion 
day 
1 2 1 2 1 2 1 2 
Volume 
(mL) 
5.1 4.0 4.2 4.4 4.2 4.4 4.1 4.0 
Valproic acid (VA); carboplatin at 0.18mg/ml (C); combined carboplatin at 0.18mg/ml with valproic acid at 14.4mg/ml (C+VA); combined carboplatin at 




Chapter 5. Clinical predictors of infusion-related toxicity during 
pontine infusion in children with diffuse intrinsic pontine glioma 




Pontine infusion of chemotherapeutics in patients with diffuse intrinsic pontine glioma 
(DIPG) is associated with neurological side-effects (Souweidane et al. 2018, 
Singleton et al. 2016). Being able to understand the neurological changes that take 
place during pontine infusion and how to prevent long-term side effects is an 
important step in the translation of this new therapy. The benefit of the chronic, 
implantable drug delivery system compared to other devices is that patients can be 
infused awake. Apart from being able to avoid repeated general anaesthetic, this 
also provides the clinician with continuous feedback about the integrity of vital neural 
structures throughout infusion.  
 
It is well understood that clinical observations are useful predictors of patient 
deterioration. Amalgamation of physiological parameters such a heart and 
respiratory rate, arterial blood pressure and oxygen saturations into early warning 
scores (EWS) are vital tools in identifying the unwell patients, guiding intervention 
and reducing harm (Downey et al. 2017). Patients with DIPG receiving infusion of 
chemotherapeutics directly into the pons are at risk of critical deterioration from 
various foreseeable causes including hydrocephalus, brainstem haemorrhage and 
ischaemic stroke. Indeed, given the experimental nature of the treatment and the 
limited understanding of the pharmacodynamics of direct intra-parenchymal and 
intra-tumoural drug administration, some risks may be unforeseeable.  As such, 
patients receiving pontine infusion reside in a critical neurological state and 
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developing method of quantifying and predicting deterioration, akin to the EWS, 
would be helpful. Chapter 3 describes the development and preliminary validation of 
the Pontine Infusion Neurological Evaluation Score (PINEScore), which was 
designed to measure the complex neurological changes taking place in children with 
DIPG receiving pontine infusion. We hypothesized that neurological changes taking 
place during the infusion can be used to identify risk factors for persistent 




Data from 55 pontine infusions in 8 children with DIPG as described in Chapter 4 
were analysed. PINEScores were measured by the attending nursing staff before 
each infusion commenced and at every hour during infusion until the end. If children 
remained on Paediatric Intensive Care Unit (PICU) after the infusion had finished, 
PINEScores were recorded until they were discharged to the ward. PINEScores 
were inputted directly onto a computer database using critical care and anaesthesia 
information software, ICIP® (Phillips, Surrey), together with the infusion rates and 
volumes per catheter, Glasgow Coma Score and cardiorespiratory parameters.  
 
Individual items of the PINEScores (i.e. headache, consciousness, ophthalmoplegia 
etc) were recorded on to a database for analysis using Microsoft ® Excel together 
with infusion rates and volumes of infusion. Statistical Package for Social Science 
(Version 23; IBM, USA) was used for statistical analysis. To accommodate for 
differing patient status at baseline, PINEScore were analysed in two ways: firstly, by 
total PINEScore and secondly by change in PINE score from pre-infusion baseline 
(∆PINE). Infusion-related side effects were identified using the PINEScore by 
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changes from pre-infusion baseline. Comparisons between PINEScores were 
performed using t-test calculation. Correlation calculations were calculated using 
Spearman’s correlation co-efficient. Frequency of side-effects was determined at the 
time of onset. Persistent deficits were defined as changes in PINEScore from pre-
infusion baseline that failed to recover after 24 hours, all other deficits were defined 
as transient. Resolution of side effects was evaluated by parent and patient interview, 
review of outpatient letters and clinical examination.  Risk of persistent deficits were 
described using odds ratios (OR).  Analysis of volume of infusion was performed 
after volumes had been rounded to the nearest integer. Statistical significance was 




55 infusions of carboplatin combined with sodium valproate were performed in 8 
children (3-11 years) as described in Chapter 4. Median PINEScore at the start of 
each infusion was 2 (range 0-16). Pre-infusion baseline PINEScores demonstrated 
weak (0.45) and moderate (0.63) correlations with numbers of infusions administered 
and days since diagnosis respectively using Spearman correlation co-efficient 
calculations, both of which reached statistical significance (p-value<0.001). Changes 
in PINEScore demonstrated the accumulation of neurological and signs and 
symptoms during infusion (Figure 5.1.)  
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Figure 5.1. Neurological signs and symptoms identified using the Pontine Infusion 
Neurological Evaluation Score (PINEScore) during pontine infusion in two children 
with diffuse intrinsic pontine glioma (DIPG). Representative graphs of neurological 
signs and symptoms identified using the PINEScore are presented for two children 
with DIPG during pontine infusion performed through two transcerebellar catheters. 
PINEScores (primary y-axis) per item are presented as stacked bar charts, with each 
colour representing a different neurological sign or symptom versus the hour of 
infusion (x-axis). Infusion volumes are presented in total (black line) and in the left 
(blue) and right (green) transcerebellar catheters (secondary y-axis) versus hour of 
infusion (x-axis). Graph A demonstrates an untitrated infusion where the infusion is 
continued despite increase in PINEScore. Graph B demonstrates the reduction in 
flow rate of the left frontal catheter at onset of increased scores pertaining to right 
upper and lower limb weakness; by the end of infusion, scores for the right upper 
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Mean PINEScore increased during infusion from 3.3 to 5.7, which differed with 
statistical significance (p-value >0.001; Figure 5.2). Mean ∆PINE increased with 
infusion and infusion volume demonstrated weak positive correlation (0.437) with 
∆PINE; this reached statistical significance using (p-value<0.001). There was no 
difference between mean PINEScore before trans-frontal and trans-cerebellar 
infusions at 3.8 and 4.0 respectively (p-value =0.89). Mean ∆PINE at the end of 
infusion, however, was greater during trans-cerebellar infusions than trans-frontal 









Figure 5.2. Changes in neurological signs and symptoms measured using the Pontine 
Infusion Neurological Evaluation Score (PINEScore) in 55 pontine infusions in 8 children 
with diffuse intrinsic pontine glioma. A. Mean PINEScore increased from 3.29 to 5.65, 
which reached statistical significance (p-value <0.000); B. Mean change in PINEScore 
increases with volume of infusion; C. Mean change in PINEScore is higher during 
transcerebellar infusion than trans-frontal infusion but this does not reach statistical 






PINEScores identified 157 symptoms during 55 pontine infusions, the most common 
of were headache (33/157) and limb weakness (49/157) (Table 5.1.). According to 
the Wong Baker Faces Scale, headache was reported as hurting ‘a little’, ‘a little 
more’, ‘even more’ and ‘a whole lot’ in 17, 11, 4 and 1 cases respectively. 74 and 50 
transient and persistent neurological deficits were identified respectively.  18 of the 
persistent deficits were present at 4 weeks’ follow-up (Table 5.1). At the onset of 
deficit, the attending physician must weigh up the benefits of continuing infusion 
versus the immediate risk to the patient and the likelihood of the deficit becoming 
persistent. In this cohort, no deficits were an immediate risk to the patient; however, 
50/124 deficits became persistent and 18 failed to recover by 4 weeks. Predicting 
non-recoverable deficits is central to managing pontine infusion safely. The ratios of 
transient and persistent deficits were calculated according to duration of deficits 
during infusion, the occurrence of the deficit during previous infusions, the maximum 
severity measured using the PINEScore and volume of infusion (Table 5.2.). The risk 
of an observed deficit becoming persistent was calculated using binary logistic 
regression (Figure 5.3.). Deficits that had occurred during a previous infusion and 
those that occurred during a trans-cerebellar infusion were more likely to be 
persistent with OR 2.333 (95% CI 1.094-4.976; p-value =0.028) and 2.155 (1.029- 
4.513; p-value=0.042) respectively. Similarly, if an infusion was stopped or titrated 
rather than continued, the deficit was less likely to be persistent, OR 0.473 (95% CI 
0.177-0.948; p-value=0.037). Other factors such as maximum severity of deficit 
(indicated by increase in PINEScore greater than 1) and duration of deficit during 
infusion longer than 3 hours trended toward increased risk of persistent deficit but 
failed to reach statistical significance. Deficits acquired after 3 mL of infusion tended 
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toward reduced risk of becoming persistent; however, they did not reach statistical 




Figure 5.3. Risk factors for persistent deficits arising from 55 pontine infusions in 8 
children with DIPG. A forest plot demonstrating unadjusted odds ratios for risk of an 
infusion-related deficit becoming persistent.  
 
After 8 infusions in 5 children (Patients D, I, J, L and M) PINEScores were recorded 
while the patient remained in PICU after the infusion had finished (Figure 5.4). This 
enabled quantification of recovery following infusion using the PINEScore. Mean 
total PINEScore and mean ∆PINE at the end of infusion was 8.6 and 6 respectively. 
After a mean recovery time of 1.5 hours total PINE Score and ∆PINE decreased to 
5.6 and 3.4 respectively; however, only changes in ∆PINE score reached statistical 
significance (p-value=0.035). When scores pertaining to headache were excluded 
these results were no longer statistically significant. 
OR 95% CI p-value
Titrated or stopped 0.473 0.177-0.948 0.037*
Duration of deficit ≥ 3 hours 1.836 0.829- 4.066 0.135
Transcerebellar infusion 2.155 1.029-4.513 0.042*
Maximum severity > 1 1.889 0.899-3.97 0.093
Incidence more than once 2.333 1.094-4.976 0.028*












Figure 5.4. Recovery of neurological signs and symptoms using the Pontine Infusion 
Neurological Evaluation Score (PINEScore) after end of pontine infusion in patients 
with diffuse intrinsic pontine glioma (DIPG) A. A representative graph demonstrating 
reduction in PINEScore following cessation of infusion in a patient with DIPG. B. 
Mean PINEScore and change in PINE Score from pre-infusion baseline at the end of 
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Neurological signs and symptoms in 8 children during 55 pontine infusions of 
combined carboplatin and sodium valproate were systematically monitored using the 
PINEScore. The PINEScore increased during pontine infusion reflecting the 
accumulation of neurological signs and symptoms during infusion. Headache was 
the most common symptom. All patients developed an infusion-related deficit, the 
most common of which was limb weakness and nearly half of deficits went on to be 
persistent. This is the first time the neurological deterioration during pontine infusion 
has been quantified and represents an avenue for improving its safety. Data derived 
from the PINEScore suggests that deficits have occurred previously during an 
infusion or occur during a trans-cerebellar infusion are more likely to be persistent 
and that the risk of a deficit becoming persistent is less likely when the infusion is 
either stopped or slowed immediately. Other factors that may be associated with 
neurological recovery include the severity and duration of deficits during infusion.  
 
There are several caveats to this analysis. This data is derived from a scoring 
system that has not been rigorously validated and its normative values are unknown. 
It has been used outside an experimental protocol and the recovery of deficits were 
defined retrospectively. Nursing staff were unblinded to the infusion volumes and the 
titrations. It is possible that PINEScores may be biased by preconceived ideas about 
how patients respond during infusion. Furthermore, intra-rater variability of the 
PINEScore is unknown and therefore may not be reliable when quantifying recovery 
or deterioration between infusions. There is also no understanding of what change in 
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PINEScore is clinically significant. The addition of a time point to record PINE Scores 
after infusion would also help quantify recovery. 
 
Despite these limitations, it is essential that the safety of CED in DIPG is improved 
and the impact of treatment on the quality of life is reduced. Bearing in mind 
conventional neurological monitoring is insensitive to many of the signs and 
symptoms provoked by pontine infusion, it is important that we learn as much as 
possible from this preliminary experience before the treatment is extended into a 
clinical trial. It would appear that the neurological injury during pontine infusion is 
accumulative. Total PINEScore was positively correlated with the number of 
infusions. The risk of a deficit being persistent was also increased if it had occurred 
during a prior infusion. Admittedly, this could be confounded by progression of 
disease because deficit incidence and number of infusions are also co-correlated 
with time from diagnosis. However, considering that these infusions were performed 
prior to diagnosis of clinical and radiological progression it is likely that the infusion is 
still an important contributory factor to the accumulation of neurological deficits over 
time. Therefore, reducing the frequency of neurological side-effects during infusion 
would be advantageous.  
 
It is evident that 30% of the recorded deficits occurred <1mL infusion. Interestingly, 
deficits occurring at the end of infusion were less likely to become persistent. It 
would appear that risk of persistent side-effects are not dependent on volume of 
infusion. This is encouraging because we may still be able to maximise volume of 
infusion to treat the peri-tumoural brain without necessarily exposing the child to 
more risk. The risk of persistent side-effects was increased if the infusion was 
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continued rather than stopped or reduced and tended toward greater risk of 
persistence if the infusion was continued for 3 or more hours after deficit onset. This 
would suggest that the way in which the infusion is conducted is a key determinant of 
treatment-related morbidity. Responsive and prompt infusion adjustment may help to 
improve the safety profile. Time is Brain is a mantra of modern stroke medicine, 
emphasizing the time-sensitive therapeutic window to relieve brain ischaemia and 
reduce brain injury (Hill and Hachinski 1998). This evidence suggests that this 
principle may also apply to pontine infusion, immediately stopping or reducing the 
infusion into the pons may reduce the risk of long-term deficits - presumably due to 
the relief of pressure on eloquent neural structures.  
 
In the early experience of using carboplatin and sodium valproate as monotherapies, 
it was thought that neurological side-effects were difficult to avoid in pontine infusion. 
However, these data suggest that if the risk factors for persistent deficits can be 
avoided the accumulative damage from successive infusions could be lessened. 
Exactly, how this can be achieved remains to be seen. However, considering that 
most deficits occurred in the first 2 ml of infusion and the longer a deficit persists the 
more likely it is to be permanent, a slower ramping regime with a more responsive 
approach to onset of symptoms may help to reduce early deficits treatment-related 
morbidity.  
 
Although these data are able to describe the pattern of deficits occurring during 
pontine infusion, the cause (or causes) remain unknown. There are three obvious 
factors to consider when exploring the sources of treatment-related morbidity; the 
underlying brain, the physiological effect of the infusion and the pharmacological 
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toxicity of the drug. Originally, the drug has been a prime suspect as the cause of 
morbidity. Carboplatin is neurotoxic, which is thought to be brought about by a 
combination of nuclear and mitochondrial DNA damage, action on ion channels and 
microglia cells (Kanat, Ertas and Caner 2017, Avan et al. 2015). While, on the other 
hand, sodium valproate can result in encephalopathy and parkinsonism (Jamora et 
al. 2007, Gerstner et al. 2006). The drugs in solution also possess high osmolality. 
Injection of hyperosmolar solutions into the ventricles causes fluid shifts between 
different fluid compartments within the central nervous system (Krishnamurthy et al. 
2009). Abnormal fluid shifts due to intra-tumoural drug administration could therefore 
result in critical increase in intra-pontine pressure. The pharmacodynamic 
characteristics of sodium valproate and carboplatin together with the hyperosmolarity 
of the drugs’ excipients could cause significant neuro-toxicity.  
 
However, there is evidence to suggest there may be other factors responsible. The 
combination of sodium valproate and carboplatin has not been found to be directly 
neuro-toxic in preclinical models (Killick-Cole et al. 2017). The onset of deficit is rapid 
during infusion, with 30% of side-effects occurring within the first millilitre of infusion, 
possibly too soon for any carboplatin-mediated DNA damage or inflammation to take 
place. Carboplatin resides in the brain for at least 24 hours when delivered by CED 
(White et al., 2012). There was evidence of recovery immediately after infusion even 
though local drug concentration would still have been high.  Also, it appears that the 
way the infusion is conducted seems to be associated with risk of deficits becoming 
persistent. Notably, neurotoxicity is often a delayed complication of carboplatin 
treatment and there was no clear evidence of toxicity arising after the infusion had 
finished suggesting that delayed carboplatin-mediated toxicity had not taken place. 
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Furthermore, the side-effect profiles of cranial neuropathy, ataxia and limb 
weaknesses were similar using carboplatin alone, sodium valproate alone, in 
combination and at different respective concentrations (Singleton et al. 2016; see 
Chapter 2 and 4).  Indeed, the side-effects described by Souedaine et al., were also 
very similar (Souweidane et al. 2018b) despite using a totally different infusate. 
Patients receiving sodium valproate by monotherapy had a simultaneous four-
catheter infusion, which was associated with the significant neurological deficits that 
failed to recover while combined therapy performed using a two-catheter infusion 
was only associated with mild-moderate deficits. The maximum rate of infusion 
occurring during a 4 catheter infusion and a 2-catheter infusion is 1.2 ml/hr and 0.8 
ml/hr respectively. Taken together, this would suggest that the infusion itself is an 
important cause of the observed toxicity.  
 
So what could it be about the infusion that gives rise to such neurological side effects? 
Previously, it was thought that the anatomical position of the catheters was a key 
determinant of the side-effect profile. Indeed, the first patient to receive sodium 
valproate by pontine infusion developed immediate facial palsy, which was improved 
when a catheter adjacent to the facial colliculus was retracted (see Chapter 2). 
Indeed, onset of unilateral weakness is often improved by reducing flow into the 
contralateral pons possibly due to relief of pressure within the associated 
corticospinal tract. However, other relationships between anatomical location of 
catheters and observed deficits are more difficult to explain. For example, not all 
patients develop the same neurological symptoms despite catheters being in broadly 
comparable brain regions. This could be due to several reasons. Multiple catheters 
still infuse concurrently preventing accurate localisation of a deficit to a specific 
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catheter. The tangential trajectory of catheters across the midline could also prevent 
lateralisation of deficits. The complex anatomy and decussation of neural structures 
within the pons and their distortion by the underlying tumour may also make 
localisation challenging. Different neural structures may also recover at different 
rates. After reduction of flow rates some deficits may not immediately improve, which 
could make interpretation of cause and effect more difficult. Neural damage due to 
the tumour is also not uniform and abnormal tumour architecture could result in 
heterogeneous fluid distribution.  Beyond this complexity, a key principle of caring 
for the neurologically injured patient is the Munroe-Kelly Doctrine, which stipulates 
that the skull is a fixed vault, containing blood, brain and cerebrospinal fluid.  Their 
volumes exist in an equilibrium where increase in one would result in ‘water or other 
matter effused or secreted… out of the cranium” (Munroe 1783). Indeed, this 
equilibrium is responsible for maintaining safe intracranial pressure (ICP), which in 
turn determines the pressure gradient across the brain capillary bed, known as the 
cerebral perfusion pressure (CPP). CPP is determined by: 
 
𝐶𝑃𝑃 = 𝑚𝑒𝑎𝑛 𝑎𝑟𝑡𝑒𝑟𝑖𝑎𝑙 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 − 𝐼𝐶𝑃 
 
During pontine infusion, there is evidence of raised ICP. Patients complain of 
headache and have reported vomiting. Given that the level of consciousness is 
rarely impaired during pontine infusion, it is unlikely that global CPP becomes 
critically low. But, generating high local pressure by continuous infusion is still the 
core principle of CED and, therefore, in these children intra-pontine pressure is still 
likely to be high (Bobo et al. 1994). A possible cause of the observed neurological 
toxicity could be the development of localised perfusion deficits within the pons. 
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Considering that perfusion in DIPG varies between patients and within tumours 
(Sedlacik et al. 2013); this may explain why some neurological signs and symptoms 
are not easily localised to certain catheters and also vary between patients. Indeed, 
the time dependent features of infusion-related deficits are also reminiscent of Stroke 
Medicine’s ‘time is brain’. Prompt relief of pressure by stopping infusion or reducing 
flow rate into critically ischaemic parts of the pons may allow adequate reperfusion 
and prevent ongoing injury.  
 
Regardless of the underlying cause of these deficits, many of these hypotheses can 
only be tested in human subjects. As described, the neurological phenotype arising 
during pontine infusion is likely a product of the interaction between the location of 
the catheters, the pattern of fluid distribution and pathology of the underlying tumour. 
This requires a reliable means of quantifying neurological change, which would be 
hard to achieve in an animal model. Consequently, as well as developing novel 
clinical tools to monitor pontine infusion, another important step in the translation of 
CED for DIPG is the need to develop imaging techniques to quantify events at a 
tissue level.  
 
In summary, this chapter presents findings from 55 pontine infusions in 8 children 
with DIPG. Analysis of neurological signs and symptoms occurring during pontine 
infusion using the PINEScore demonstrated that risk of persistent deficits were 
higher if the infusion was not promptly adjusted and if the deficit had occurred during 
a prior infusion. If catheter flow was adjusted based on anatomical position some 
deficits would recover. This suggests that the neurological damage arising from 
pontine infusion can be localised, it is time dependent and accumulative. 
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Development of imaging techniques will enable better understanding of the aetiology 





Table 5.1. Transient and persistent neurological deficits acquired during 55 pontine 














Reduced level of consciousness 1 0 0 
Ophthalmoplegia 5 8 4 
Facial dysesthesia 0 0 0 
Facial weakness 12 6 3 
Tongue weakness 2 2 0 
Dysarthria 12 5 1 
Body dysesthesia 1 0 0 
Limb weakness 25 24 8 
Limb ataxia 16 5 2 
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Table 5.2. Frequency of transient versus persistent neurological deficits according to 
duration of deficit, maximum severity, action taken, incidence of deficit, infusion 



















0 hours 13 6 0.46 
1 hour 11 4 0.36 
2 hours 13 8 0.62 
3 hours 6 6 1.00 
≥4 hours 31 26 0.84 
What was the maximum severity of the 
deficit measured by the PINEScore*? 
  
 
1 point 49 27 0.55 
≥2 points 23 23 1.00 
What action was taken at onset of deficit?    
Infusion was continued 46 40 0.87 
Infusion was titrated immediately 17 7 0.41 
Infusion was stopped immediately 11 3 0.27 
How many times has the deficit occurred 
during a previous infusion? 
  
 
Never 37 15 0.41 
Once 15 14 0.93 
Twice 10 9 0.90 
Three or more times 11 12 1.09 
Did the deficit occur during a trans-frontal 
infusion or a trans-cerebellar infusion? 
  
 
Trans-frontal infusion 45 22 0.48 
Trans-cerebellar infusion 27 28 1.03 




≤1 mL 24 14 0.54 
1-2 mL 13 13 1.00 
2-3 mL 12 14 1.17 
3-4 mL 14 5 0.36 
4-5 mL 11 4 0.36 




Chapter 6. Development of quantitative MRI techniques to 





Treating children on compassionate grounds with carboplatin and sodium valproate 
delivered by pontine infusion has been associated with better than expected survival 
in patients with diffuse intrinsic pontine glioma. However, this new treatment was 
also associated with neurological morbidity. The Pontine Infusion Neurological 
Evaluation (PINE) Score was used as a measure of neurological deterioration during 
infusion and demonstrated that much of this observed neurological morbidity is likely 
to be infusion-related rather than due to the toxicity of the drug. The cause of such 
infusion-related toxicity is unknown.  
 
Exploring this question is limited by the lack of an appropriate animal model. The 
major model for chronic intermittent convection enhanced delivery uses pigs 
(Bienemann et al. 2012). Pigs share much structural homology with the human brain; 
they are gyrated (gyrencephalic) as opposed to smooth (lissencephalic) and the 
porcine brainstem has been described in detail (Hofman 1985, Freund 1969). 
However, the characteristics of structurally normal brain is likely to differ significantly 
from tumour, which makes healthy pigs a poor model to understand the deterioration 
observed in children with DIPG. Animal models of DIPG use mice and rats 
(Misuraca,, 2015). But, rodent models of CED rely on one-off or repeated 
cannulation of the brain (Arshad et al., 2015, Bienemann et al., 2012). This creates a 
tract that may allow drug to reflux and pressure to dissipate, mitigating possible 
mechanisms contributing to infusion-related toxicity. A disease model in a large 
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animal would be helpful. Indeed, brainstem glioma is reported in dogs (Mateo et al. 
2013, Petrukovich and Kilburn 2015, Cervera et al. 2011), but their treatment with 
chronic intermittent CED in an experimental setting is limited. Consequently, the best 
subjects to understand the basis of infusion-related toxicity in children with DIPG 
may be the patients themselves. As such, peri-infusion imaging presents a valuable 
opportunity to understand the basis of infusion-related toxicity during CED at the 
tissue level.   
 
Patients receiving CED routinely undergo magnetic resonance imaging (MRI) before 
and after infusion (Barua et al. 2013, Barua et al. 2016, Singleton et al. 2016). MRI 
has been used to describe a range of phenomena in drug delivery including 
quantifying tumoural response and local drug concentrations. However, analysis has 
focused on quantification of drug distribution, which is used as a metric of catheter 
efficiency (Mardor et al. 2001) and an factor of therapeutic efficacy (Mueller et al. 
2011). Hence, this has been the major emphasis of previous literature on the topic 
(Bernal et al. 2014, Chittiboina et al. 2014, Dai et al. 2016, Dickinson et al. 2008, Kim 
et al. 2009, Krauze et al. 2005, Lonser et al. 2002, Magdoom et al. 2014). This 
chapter aims to describe how MRI could be used to understand infusion-related 
toxicity.  
 
MRI uses a combination of a strong magnetic fields and radiofrequency to determine 
different densities of protons within body tissues. T1 and T2 weighted MRI can be 
used to describe water molecules in terms of their concentration, their orientation 
and physiochemical environment (Mathur-De Vre 1984). Increased T2 signal MRI 
can identify increased extracellular water during CED (Sampson et al. 2007). 
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However, in other disease states MRI can also be used to identify intracellular water 
accumulation. Diffusion weighted imaging (DWI) measures the Brownian motion of 
water molecules within in a voxel of tissue. Changes in the DWI signals can be used 
in the diagnosis and treatment of various neurological diseases:  
 
 Early diagnosis of ischaemic stroke and differentiation of acute stroke from 
chronic stroke 
 Differentiating epidermoid from arachnoid cysts 
 Differentiation of abscesses from infective cysts 
 Assessment of Creutzfeld-Jacob Disease 
 Differentiation of diffuse temporal glioma from herpes simplex 
 Grading of intrinsic and extrinsic brain tumours 
 Assessment of active demyelination 
 
DWI signal can be quantified in many ways. However, apparent diffusion co-efficient 
(ADC) remains the most commonly used in clinical practice. ADC measures 
diffusivity and values decrease in disease states where Brownian motion of water is 
reduced. This can be used to identify cytotoxic oedema arising from stroke.  A 
possible cause of infusion-related deficits may arise from localised brainstem 
ischaemia leading to stroke. During stroke there is a metabolic failure brought about 
by hypoxia. This results in failure of membrane adenosine triphosphate pumps 
resulting in intracellular water accumulation. This chapter explores how changes in 





MRI before and after pontine infusion was included in the standard operating 
procedure of pontine infusion. Children with DIPG receiving pontine infusion with 
carboplatin and valproate as monotherapies or in combination underwent imaging 
acquired on a 1.5 Tesla Seimens Aera as tolerated. In addition to T1-weighted and 
T2-weighted images, DWI imaging were acquired at 3 b-values (0, 500, 1000) 
consistent with protocols designed to identify ischaemic brain (Shen et al. 2011).  
 
MRI post-processing was performed using FSL for brain extraction and registration 
(Smith et al., 2014). Pre-infusion MRI was then floated onto post-infusion MRI using 
three-dimensional rigid registration. In order to compare changes in ADC in the same 
anatomical space, a cube (18 voxels3) was selected as a region of interest using ITK 
Snap®. The cube was located on pre-infusion MRI by centring the cube at the 
intersection of two lines drawn from the lateral floor of the fourth ventricle to the 
contralateral temporal uncus on each side (Figure 6.1). MatLab® was used to 
measure absolute mean ADC values for each region of interest both pre- and post-
infusion. Differences between mean ADC values were calculated by subtracting the 
mean ADC of the post-infusion MRI from the pre-infusion MRI on a voxel-voxel basis. 
Statistical significance was measured using a Wilcoxon Signed Rank Test and Chi 








Figure 6.1. The Pontine Cube: Reference space. Analysis was conducted within an 
18 voxel cube centred on the intersection between two lines drawn between the 




5 infusions in 3 children had both a pre-infusion and a scan performed immediately 
after infusion scan sequences for T2*, fluid attenuated inversion recovery (FLAIR) 
and diffusion weighted imaging (DWI). Four infusions had post-infusion scans 
deferred to the following day. One post infusion scan was delayed until after the 
second infusion. The remaining infusions either did not have post-infusion imaging 
performed or available DWI sequences.  Reasons for scans being delayed were due 
to infusions continuing beyond working hours where a MRI radiographer was no 
longer available. Scans after infusions were also not performed if they would not 
tolerate the MRI without a general anaesthetic. 
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Overall, mean ADC values increased after pontine infusion from 0.831 m/s to 0.840 
m/s, which did not reach statistical significance (p-value=0.182; Table 6.1). However, 
this observation was not consistent amongst all 3 patients. 2 patients demonstrated 
right-ward shift in ADC values and one patient demonstrated no change in 
distribution of ADC values after infusion (Figure 6.2). The number of voxels with ADC 
values <0.6m/s, a value consistent with ischaemia, were calculated before and after 
infusion. The total number of voxels <0.6m/s before and after infusion were 434 and 
277 respectively, which reached statistical significance (p-value=<0.001) (Table 6.1). 
Again, this reduction in the number of voxels with ADC <0.6 m/s was not consistent 
across all infusions. Three infusions were associated with a increase in the number 





Figure 6.2. Histograms of apparent diffusion co-efficient values pre- and post- 
infusion in 5 infusions in 3 children with diffuse intrinsic pontine glioma.   Histograms 
are taken from cycle 3 and 4 of patient D (A and B), cycle 4 and 5 of Patient J (C and 
D) and cycle 2 of Patient L (E). 
 
The tumour microenvironment is heterogeneous and although mean diffusivity may 
be higher following infusion there still may be localised perfusion deficits arising from 
a combination of the anatomical arrangement of the catheters, asymmetric drug 
distribution, the vascular network of the tumour and the complex anatomy of the 
underlying pons. As such, diffusivity was compared before and after infusion within 
the region of interest voxel by voxel (Figure 6.3). This demonstrated that ADC values 
both increased and decreased during infusion depending on location within the pons 
(Figure 6.3). More voxels increased than decreased at 4086 and 4014 following 
infusion respectively, but this did not reach statistical significance (p-value=0.264) 
(Table 6.1). This suggests that changes in diffusivity occurring during infusion are 














Figure 6.3. Anatomical heterogeneity of apparent diffusion co-efficient (ADC) shift in 
3 children with diffuse intrinsic pontine glioma. Post-infusion images were registered 
to pre-infusion images. The reference space was divided into voxels. Post infusion 
voxel values were subtracted from pre-infusion voxel values in an anatomically 
specific manner (A). Representative maps from 3 patients are shown showing post-
infusion and pre-infusion ADC maps: lower ADC values are indicated by darker 
colours. Subtraction Maps were generated by subtracting pre-infusion voxels from 
post-infusion voxels. Binary Maps demonstrate voxels that increased diffusivity 




















This exploratory analysis aimed to develop quantitative fully automated MRI 
techniques to describe the physiological processes taking place during pontine 
infusion. The results demonstrate that ADC following infusion results in 
heterogeneous changes both between patients and within tumour. Using ADC 
mapping, there was no evidence that ischaemia was taking place during infusion. 
 
There are several limitations to this imaging study. A small number of patients were 
used and different volumes of infusate were administered on each occasion. The 
contribution of tumour characteristics to changes in diffusivity is also unclear. Notably, 
one patient demonstrated very little change in mean diffusivity while other patients 
demonstrated increase in mean diffusivity. The extent to which this reflects individual 
particularities of drug distribution, cellular architecture of the underlying tumour or 
efficiency of drug delivery remains to be seen. This limited analysis would be 
benefitted by volumetric analysis and quantitative assessment of accompanying T2* 
and T1 signal intensity. The absence of follow-up imaging would also be useful to 
delineate the underlying physiological processes taking place. In stroke, for example, 
DWI undergoes a stereotypical transformation relative to the age of infarct.  
 
Despite the limitations of this study, it was evident that pontine infusion in some 
cases increased diffusivity. This likely represents an increase in free water molecules 
arising from direct intra-parenchymal infusion. Use of DWI has been used previously 
to estimate volume of distribution in experimental models. Iyer et al., 2011, infused 
non-human primates with radiolabled dextrose and sucrose demonstrating that the 
volume of distribution using T2, DWI and autoradiographic studies were co-
correlated. Clinically, T2-weighted imaging has been used to estimate drug 
distribution (Barua et al., 2013; Barua et al., 2016). This is despite evidence that T2-
weighted imaging cannot demonstrate drug distribution in oedematous brain and the 
boundaries between infused and uninfused brain are dependent on user-defined 
intensity thresholds (Sampson et al., 2007). Such methods may be vulnerable to bias 
and may inadequately evaluate infusion efficacy and catheter efficiency. Considering 
that infusion volumes are maximised to increase the volume of distribution, which in 
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turn is associated with ongoing risk to the patient, an objective method of quantifying 
drug distribution is essential. The method described herein does not help delineate 
the boundary between infused and un-infused brain but it does use a fully automated 
quantitative approach to quantify drug delivery in abnormal brain, which could be 
developed further.  
 
The use of MRI in CED at present is still confounded by many important factors. It 
may be that quantifying volume of distribution using MRI will never truly represent 
drug distribution at a molecular level. Iyer et al., demonstrated that volume of 
distribution using T2, DWI and radiolabelling co-correlated, but MRI quantification 
underestimated the volume of distribution compared to radioanalysis. Such error 
could be overcome by co-infusion of tracers such as gadolinium, which can 
accurately model the volume of drug distribution (Mehta et al., 2011). But, such a 
technique assumes that the drug and tracer distribute equally through tissues and 
maintain the same tissue half-life. Indeed, more recently gadolinium has been shown 
to deposit in the brain, the clinical significance of this is unknown (Guo et al, 2018).  
Considering the neurological morbidity associated with pontine infusion, delivery of a 
therapeutically inert substance at the risk of neurological compromise raises an 
ethical dilemma. It is possible to bind drug to tracer molecules to overcome these 
limitations (reviewed in Mehta et al., 2011). However, this could alter the therapeutic 
efficacy and toxicity of the drug. Given these limitations, the complexity of modelling 
drug distribution may require a more pragmatic method of assessing drug delivery 
and therapeutic efficacy. Changes in MR Spectroscopy, for example, have been 
used to quantify local tumour response and subsequently infer efficacy of drug 
delivery in CED (Guisado et al., 2016).  Another approach could be monitoring of 
disease response within a reference space where there is objective evidence of drug 
delivery. Longitudinal measurement of contrast enhancement, DWI and T2 weighted 
signal intensity can indicate tumour progression and response (Elllingson et al., 2017, 
Chang et al., 2017, Radbruch et al., 2012). Tracking these characteristics this within 
the central pontine cube described herein may help better understand the 
association between drug delivery and treatment effect. 
 
It must also be acknowledged that increase in diffusivity during infusion may be due 
to other factors than drug distribution. Tumours are hypercellular and restrict the 
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movement of water molecules with their cell membranes, macromolecules and 
irregular extracellular spaces; this reduces ADC. When tumours are treated with 
anticancer therapy there is resultant necrosis, apoptosis and cell lysis leading to 
increased mobility of water within tissues, which should increase ADC (reviewed in 
Afaq et al., 2010).  It is possible therefore that a contributor to rightward shift in ADC 
may represent tissue lysis. Indeed, vacuolation at the end of catheter has been 
observed in patients with CED (Figure 6.4). We may be able to use DWI to 
determine critical levels of tissue tolerance and reduce structural damage resulting 











This chapter fails to answer if neurological deterioration in pontine infusion is due to 
an underlying ischaemic process. Net increase in diffusivity after CED may not 
necessarily mean ischaemia is absent at a cellular level. In acute stroke, DWI 
indicates ischaemia by reduction in ADC within a brain volume reflecting pathological 
cytotoxic oedema (Schaefer et al., 2000). Signal from increased extracellular free 
water or tissue lysis arising during CED may overwhelm any change in ADC arising 
from a simultaneous ischaemic process. Other methods to identify ischaemia may 
help to identify underlying ischaemia, such as measurement of cerebral blood flow 
(CBF). CBF can be measured by dynamic susceptibility contrast (DSC) MRI, using 
exogenous contrast, or by arterial spin-labeling (ASL) MRI that magnetically tags 
water molecules in blood (reviewed in Muir et al., 2014). Both techniques have been 
A B 
Figure 6.4. Vacuolation along a catheter trajectory following pontine 
infusion. Mid-sagittal plane of T1-weighted magnetic resonance image 
sequence with contrast before pontine infusion (A) and after pontine 
infusion (B) in a patient who received carboplatin monotherapy. 
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used to diagnose stroke (Copen et al., 2012). However, evaluating intra-tumoural 
ischaemia requires validation in animal models and could be complicated by the 
already hypoxic microenvironment of DIPG (Yeom et al., 2015). Nevertheless, such 
techniques may be useful in delineating the cause of neurological deterioration 
during pontine infusion and in time help to prevent long-term disability.   
 
In summary, this chapter demonstrates the development of a fully automated 
quantitative method of evaluating pontine infusion using MRI. Increase in diffusion 
after CED likely represents local drug delivery; however, this also could represent 
other processes such as tumour lysis. It does not show that neurological 
deterioration during infusion is due to ischaemia but suggests that other MRI 
modalities may be required to reject this hypothesis.  Nevertheless, CED is a 
developing field. Advances in drug delivery system design need to be matched by 
advances in methods to evaluate their effect on the patient and the underlying brain. 
This fully automated method of image acquisition, registration and quantitative 
analysis could provide important insight into the physiological processes taking place 
during direct intra-parenchymal infusion.
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Chapter 7. Reflections on the CED-DIPG Program 
 
 
This thesis describes the treatment of 15 children who underwent pontine infusion  of 
chemotherapeutic agents by convection enhanced delivery (CED) for the treatment 
of diffuse intrinsic pontine glioma (DIPG) on compassionate grounds. The DIPG-
CED treatment programme, which uses an experimental chronic, implantable drug 
delivery system, began after a small number of children DIPG were treated with 
carboplatin monotherapy (Singleton et al., 2016). There were encouraging signs of 
efficacy with  children surviving longer than the expected median survival of 11. 1 
months (Veldhuijzen van Zanten et al., 2017). However, the treatment was 
associated with neurological side-effects. These were thought to occur after infusion, 
and their aetiology was attributed to the pharmacological toxicity of drug, which is a 
well established problem in modern oncological practice. 
 
Figure 7.1. Survival curves for 15 children with diffuse intrinsic pontine glioma (DIPG) 
treated with chronic intermittent convection enhanced delivery on compassionate 


































Patients in the DIPG-CED programme went onto receive, a histone deacetylase 
inhibitor, sodium valproate, which is where this thesis begins. Sodium valproate was 
intended to functionally target the histone mutations that characterise DIPG (Killick-
Cole et al., 2017). As a widely used anti-epileptic drug it was expected that sodium 
valproate would be better tolerated when delivered by CED compared to carboplatin. 
However, like carboplatin, treatment was associated with neurological side-effects 
but whether the toxicity arose from the pharmacological effect of the drug or the 
effect or the infusion was still unclear.  
 
DIPG is almost universally fatal, the process of dying is often rapid and debilitating - 
maximising quality of life of in these circumstances is paramount (Veldhuijzen van 
Zanten et al., 2017; Veldhuijzen van Zanten et al., 2016).   The aim of this thesis was 
to develop methods of understanding the aetiology of toxicity arising from pontine 
CED, with a view to reducing the burden of treatment and helping build CED into a 
feasible treatment option for DIPG. I developed, implemented and evaluated a novel 
neurological assessment tool to quantify neurological deterioration during pontine 
infusion. The Pontine Infusion Neurological Evaluation (PINE) Score, as it is called, 
was adapted from established methods of neurological examination and was found 
to be excellently reliable when  comparing results between examiners.  For the first 
time it was possible to quantify accumulating neurological disability during infusion. 
Patients went onto receive a combination of carboplatin and sodium valproate, 
based on the rationale that carboplatin and sodium valproate worked synergistically 
in vitro (Killick-Cole et al., 2017). However, side-effects were still significant but the 
PINEScore enabled these neurological side-effects to be studied in more detail. This 
helped to identify risk factors for persistent deficits arising from infusion. Deficits 
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were more likely to be persistent if the child had sustained the deficit during a 
previous infusion and if the infusion was continued rather than stopped or slowed at 
deficit onset. Taken together, this suggests neurological injury from infusion is 
accumulative and possibly time dependent akin to the 'time is brain' paradigm of 
Stroke Medicine (Hall & Hachinski, 1998). Deficits whilst infusing into the lateral pons 
through transcerebellar catheters were also associated with a higher risk of 
becoming persistent. Whether this represents a particular vulnerability of structures 
in the lateral pons or that most transcerebellar infusions were conducted on the 
second day of the each cycle remains to be seen.  In addition, duration of deficit 
longer than 3 hours and more severe impairments trended toward persistent deficits. 
 
The frequency of neurological side-effects at the time of administration, strongly 
suggests that the observed neurological toxicity is due to events occuring during 
infusion. In contrast to earlier experience treating children with carboplatin (Singleton 
et al., 2016), there was little evidence that neurological deficits occurred after 
infusion. It may be that the implementation of a systematic neurological assessment 
method allows intra-infusion disability to be recognised more readily. Before the 
implementation of the PINEScore, some deficits may have only been identified when 
the patient had resumed their normal activities. The cause of these infusion-related 
deficits is unknown.  
 
Nevertheless, possible explanations could be broadly divided into two categories: 
either by rapid onset of pharmacological toxicity caused by the drug or physiological 
stress caused by the infusion. This thesis provides evidence to suggest that the latter 
should be a priority for further investigation. Firstly, many of the factors associated 
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with persistent deficits, i.e. action taken during infusion, site of brain infused and time 
to infusion adjustment relate to how the infusion is conducted. Secondly, carboplatin 
and sodium valproate were associated with similar toxicity profiles, both singly and in 
combination. Indeed, Souweidaine et al,. 2018 in their Phase I trial infusing a 
radioimmunotherapeutic agent by CED demonstrated similar signs and symptoms of 
cerebellar dysfunction, limb weakness and cranial neuropathy at one week post-
infusion. The similarity in observed side-effects after infusion is in spite of the very 
different pharmacokinetic and pharmacodynamic characteristics between the drugs. 
Finally, the PINE score showed signs of immediate clinical improvement following 
infusion adjustment eventhough local tissue concentrations would still have been 
high. The exact physiological processes underpinning neurological deficits is 
unknown and should be considered in further preclinical experiments. This thesis 
puts forward the idea that they could be related to ischaemia. Development of a 
quantative MRI protocol to address this hypothesis was unable to exclude or confirm 
the presence of ischaemia during pontine infusion, but could form the basis for 
further analysis. 
 
There are many positive findings that show great promise for the treatment. Patient's 
survived longer than expected for the wider DIPG population. Patient A 
demonstrated disease response following treatment with sodium valproate. Patient D 
and J progressed outside the volume of infusion suggesting that CED was able to 
achieve local control of disease. We were able to achieve repeated pontine infusions 
in 14 of the patients implanted with the device.  Evidence that side-effects of CED 
are due to infusion means the treatment burden could be improved by adjustment of 
infusion parameters. Infusion-related deficits were not volume dependent, i.e. deficits 
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acquired at greater than 3 mL volume of infusion were paradoxically less likely to be 
persistent.  Pontine infusion could potentially be performed long term and achieve 
even greater volumes of infusion providing asymtpomatic infusions can be achieved. 
Further to this, no systemic toxicity was identified, which could pave the way for 
children with brain tumours to receive anatomically targetted therapy whilst avoiding 
the side-effects of systemic chemotherapy.  
 
These conclusions are made, however, with several important caveats. Patients 
survived longer than expected compared to the wider DIPG population. The children 
implanted with the drug delivery system had a median suvival of 13. 9 months, with 5 
children surviving over 20 months. Although, this is encouraging, it must be 
acknoweldged that these patients represent an extraordinary sample  of children. 
Their families have sort experimental treatment, mostly in a country foreign to their 
own and at significant personal expense. They were also selected on the basis of 
radiological and clinical factors that made implantation of the drug delivery system 
feasible at a time when a proportion of patients would already have had advanced 
disease or died. The extent to which these biological and sociological factors 
impacted survival remain to be seen. Moreover, many patients went onto receive 
additional experimental therapies and the contribution of this to the observed survival 
is unknown. As such, the extent to which results from these patients can be 
extrapolated to the treat DIPG as a whole is limited and needs to be interrogated in a 
controlled trial. Experience from these children demonstrates that this treatment is 
feasible, and if combined with an appropriate method of clinical monitoring as 
described in this thesis, it could be delivered safely. Conclusions regarding the risk 
factors for persisient infusion-related deficits are limited by how the PINEScore has 
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been implemented and validated, which again should also be further explored in a 
clinical trial. The robustness of the PINEScore would be improved by assessment of 
intra-rater reliability; this would provide reassurance that the PINEScore could 
assess recovery and deterioration between as well as during infusions. The 
PINEScore was validated in children in various stages of middle childhood and early 
adolescence and data was derived from a very small number of children. Patients 
had different nationalities and different first langauges. PINEScore data is also 
collected from nursing staff with different levels of training and experience. Hence, in 
future the use  of the PINEScore should be used after appropriate competency 
assessment to ensure a standard quality of examination.  In addition, diagnosis of 
transient and persistent deficits, on which much of this analysis relies, would be 
better recorded by an independent investigator blinded to the treatment received.  
 
Depite these limitations, treating patients on compassionate grounds offered a 
valuable opportunity to learn how to deliver drugs safely into these tumours and have 
yielded some encouraging results. Such practice outside a clinical trial still raises a 
number of ethical issues. Compassionate use is a means of providing seriously ill 
patients with access to experimental treatment. Justifications for such therapy can be 
broadly categorised into fairness, a will to improve the patient's outcome and to 
facilitate autonomy of the patient (Raus, 2016).  
 
Compassionate use programmes can provide experimental treatment to patients, 
who would otherwise be denied access, helping to correct a perceived injustice. After 
all, why should a child be denied a potentially life-saving treatment while another is 
able to receive it? Such circumstances could arise due to the absence of an open 
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clinical trial or patient's own ineligibility due to co-existing medical problems, age or 
stage of disease. Offering dying patients who have no other treatment options 
experimental treatment is also intended to improve their outcomes. The will to offer 
treatment out of beneficence is an important and common justification for giving 
experimental treatment. Finally, out of respect for the patients autonomy, if dying 
patients "freely take on the risks of an experimental drug for the chance of great 
benefit, who are we to refuse them?" (Raus 2016). 
 
Such arguments are emotive and have lead to significant media and political 
exposure of patients being denied access to innovative therapies. There are even 
examples from patients with DIPG seeking CED (Blott, 2018). High profile Labour 
MP, Tessa Jowell, died from glioblastoma multiforme in 2018, her campaign was 
described by Sir Harpal Kumar, Chief Executive of Cancer Research UK, as ‘a call 
for more research and innovative treatments to be made available' (Drewett, 2018). 
Such attention emphasizes the urgency to improve outcomes for patients with little 
chance of cure. On a wider scale, these arguments have resulted in many US States 
to employ 'Right-to-Try’ laws, which grant seriously ill patients access to unapproved 
treatments (Zettler et al., 2014; Bateman-House et al., 2015). Social media and 
online petitions lobby governments and the medical industry to loosen regulatory 
constraints on new treatments (Mackey & Schoenfield 2016). While websites such 
as www.mytomorrows.com profit by providing access to unapproved treatment 
(Raus et al., 2016).  
 
Although, there is a social appetite for such practices, experimental treatment 
outside of a clinical trial can be problematic. Compassionate treatment is sometimes 
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justified by providing treatment to those who have been rejected from clinical trials, 
which can be perceived as unfair. It could be argued that compassionate treatment 
could only be 'fair' if it is accessible to all. But, compassionate treatment is not 
necessarily allocated in a way that is consistent. Some cases are approved following 
significant pressure from high profile campaigns while those with less successful 
campaigns are not (Mackey & Schoenfield 2016). Some pharmaceutical companies 
have to operate a lottery system to ration experimental treatment. Indeed, if patients 
are charged for the care they receive there is an obvious financial limitation that 
would deny patients who cannot afford it.  
 
Compassionate treatment can be offered out of a desire to help the patient. 
Rationally even treatments given as a part of a clinical trial, which have undergone 
stringent preclinical testing are unlikely to go onto gain approval.  26%, 34% and 
57% of drugs tested in Phase I, II and III trials respectively go onto be approved for 
clinical use (Dimasi & Grabowski, 2007). Therefore, when experimental drugs are 
accessed outside clinical trials the chance of benefit are likely to be even smaller. It 
is also acknowledged that patients treated on compassionate grounds are vulnerable 
to exploitation, which can undermine any beneficent intention all together (Raus et al 
2016). Medical industry and treating physicians can stand to make financial gain or 
can be a source of 'cheap and easy' research subjects (Raus, 2016; Werthemier, 
2008). Because compassionate treatment forms part of clinical practice, patients are 
also not protected by the same regulations used in clinical trials. There are no 
obligations to share data regarding efficacy or toxicity, to release generalizable 
conclusions by using a control group, to use peer-reviewed treatment protocols or to 
secure insurance to protect patients (Walker et al, 2014). It is arguable that such 
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risks are ameliorated when treating patients who have a palliative diagnosis. 
Denying patients experimental therapy is based on the precaution that the risks are 
unknown. Walker et al (2014) remark that this loses its 'moral force' when the patient 
is already facing death. On the other hand, for patients who have a limited life 
expectancy, quality of survival is imperative and treatment still risks causing 
unnecessary suffering. When this is combined with the financial implications of such 
treatments on patients and their families, who compassionate treatment actually 
benefits can be difficult to determine (Raus et al., 2016).  
 
However, even randomised clinical trials (RCTs), the mainstay of evidence-based 
medicine, are beset by the ethical implications when developing new treatment. 
Kodish (1991) argued that clinical trials are only justifiable if the patient can freely 
choose to participate. If new treatments are only available through RCTs then, as 
Schuklenk (2014) argues, 'dying patients are coerced into participating'. Such 
coercion undermines patient autonomy and can undermine clinical trial design. Using 
the AIDS epidemic as an example, patients 'lied and cheated to get into trials and left 
in such large numbers as to threaten the viability of the AIDS clinical trial system' 
(Schuklenk, 2014). It is argued that only with the availability of compassionate 
treatment alongside RCTs, can the patient truly assert their autonomy over using 
new therapies (Kodish 1991).  
 
Compassionate treatment could be seen to empower patient choice but ensuring 
that the patients truly have free choice is complex. Clinical trials are subject to 
research governance that safeguard how patients are consented to participate. 
Compassionate treatment is not within a construct of a clinical trial and it is offered 
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as part of clinical care. There is little to protect patients overlooking the experimental 
nature of the treatment and they could easily assume its benefits (Raus, 2016). 
When a child is recognised to have no realistic chance of cure, 20% of parents who 
opted for chemotherapy intended to cure their child while 14% were still hoping for a 
cure (Mack et al, 2008).  It is possible therefore that parents seeking experimental 
treatment for DIPG, which is terminal at diagnosis, may be particularly vulnerable 
and should be carefully protected.  
 
Nevertheless, despite the ethical challenges of compassionate treatment, the 
outcomes for patients with DIPG are poor and have not improved despite numerous 
clinical trials (Hargrave et al., 2006). Ethical deliberations about the how best to 
improve outcomes do little to extend the survival of patients who are currently being 
diagnosed. Possible solutions to accelerate access to treatment whilst generating 
robust clinical data have been suggested, these are known as adaptive trials. 
 
Traditionally, regulatory approval for a new treatment must pass through Phase I, II 
and III clinical trials: from first-in-human studies, to exploring its activity in a small 
number of patients, to comparing the new treatment against a placebo or 
conventional medical therapy. This process can take at least 7 years (Kaitlin, 2010). 
However, with increasing pressure to expedite progress, new methods of translating 
treatment from bench to bedside are being employed. In 2011, pharmaceutical 
company, Merck, conducted a first-in-human trial of immune check-point inhibitor, 
Pembralizumab, in patients with advanced solid tumours (NCT01295827). The 
impressive response rates prompted rapid increase in sample size, ultimately 
recruiting 1200 patients over the next three years. Within a short time, primary data 
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demonstrated that Pembralizumab extended survival of patients with metastatic 
melanoma, after which it became licensed for medical use. One suggestion to 
accelerate progress is that new treatments with unprecedented evidence of clinical 
efficacy should be given 'break-through status' to allow sample sizes to be expanded 
- upgrading the stage of trial seamlessly (Prowell et al., 2016). Other methods, as 
reviewed by Mahajan & Gupta, 2010, include allowing patients from early phase 
clinical trials to roll into later phase clinical trials, based on factors such as predictive 
biomarkers. 'Pick-the-winner' designs begin with several treatment arms or dosage 
schedules versus placebo. With time the best treatment strategy is continued, so at 
completion there is sufficient data to support regulatory approval for the 'winning' 
treatment. Another option is to allow trial hypotheses to be more responsive: allowing 
them to change from non-inferiority to superiority studies or switch between primary 
and secondary end-points.  Phase II and Phase III designs can be combined 
whereby a study is powered for a Phase III trial on the proviso that it successfully 
completes the Phase II 'learning' stage. Patients can also be recruited to trials where 
patients can switch between treatment if there are concerns about safety or efficacy. 
This would allow more than one treatment to be tested at once. N-of-1 trials can also 
be conducted, which are appropriate when RCTs are unfeasible due to rarity of 
disease (Collette & Tombal 2015). They provide a specific way of testing efficacy of 
two or more treatments in a single patient. This may be appropriate when studying 
slowly evolving cancers, disorders where there is an early surrogate marker of 
efficacy or treatment that may be given repeatedly without accumulative toxicity. 
Consequently, although accessing new treatment through RCTs may be too 
cumbersome for all desperately ill patients to tolerate, there are many other clinical 
 136 
study designs that have the potential to rapidly translate experimental therapies that 
avoid the pitfalls of compassionate treatment. 
 
The future of CED for DIPG 
 
So what next? Following the publication of the trial by Souweidaine., et al 2018, 124I 
coupled to B7H3 has been extended to a Phase II trial. However, while CED 
treatment schedules consist of single infusions or are conducted under general 
anaesthetic, it is likely that treatment effect will be diminished and infusion-related 
toxicity will go uncontrolled. The experience of treating patients with DIPG on 
compassionate grounds using chronic intermittent CED shows much promise for the 
future. The blood brain barrier is a major obstacle for developing new treatments for 
patients with neurological disease. Achieving high local tissue concentrations of drug 
using CED could help achieve maximum local effect and minimal systemic toxicity. 
Particularly, this technique allows patients to be infused awake allowing infusion-
related toxicity to be monitored and potentially controlled.  
 
The limiting factor for brainstem CED is sustaining local tissue concentrations 
through adequate treatment volumes for long enough to exert therapeutic benefit. 
Prolonging infusion is limited by neuro-toxicity, because pushing infusion after the 
onset of deficit is unsafe. Controlling and understanding this infusion-related toxicity 
is a rate-limiting step in performing effective CED for DIPG. This thesis argues that 
the toxicity is most likely due to physiological effects of the infusion.  Previously, 
prolonging infusion was justified in order to try and maximise the volume of treatable 
brain. Prolonged infusion was associated with accumulative neurological toxicity that 
resulted in increased recovery time, reduced treatment frequency, which overall 
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would have reduced tumoural drug exposure over time. Delivering infusions in such 
a way that patients remain asymptomatic could be achieved by reducing infusion 
volume targets or flow rates per catheter, being more responsive to clinical change 
during infusion. Also the number of implanted catheters could be increased so the 
same volume of distribution can be achieved with smaller pressure gradients at 
individual catheter tips. Minimally symptomatic infusion would allow patients to be 
infused with greater frequency thereby maintaining the high intra-tumoural 
concentrations for longer.  In the future, using this method, brainstem CED could be 
conducted at higher intensity akin to conventional chemotherapy regimens. This 
could allow patients with DIPG to complete treatment within 6-8 weeks and then 
rehabilitate enabling them to enjoy their remaining survival unhindered by prolonged 
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